Gene therapy DNA vector based on gene therapy DNA vector VTVAF17
By designing the gene therapy DNA vector VTvaf17, cloning related genes and avoiding antibiotic resistance genes and viral genome sequences, the problem of inefficiency of gene therapy vectors in the prior art is solved, and efficient expression and safety of related genes formed on extracellular matrix is achieved. Sex enhancement, suitable for the treatment of a variety of connective tissue diseases.
Patent Information
- Application Number
- CN201980093125.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-12-27
- Filing Date
- 2019-12-20
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2039-12-20
AI Technical Summary
Existing gene therapy vectors have problems with antibiotic resistance genes, viral genome sequences and non-functional sites when increasing the expression levels of genes related to extracellular matrix formation, resulting in inefficient safety and inefficiency.
A gene therapy DNA vector VTvaf17 was designed to avoid antibiotic resistance genes and viral genome sequences by cloning the coding regions of COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1 genes, and the vector length is less than 3200bp to improve infiltration Nuclear cell capacity.
It has achieved efficient expression of related genes in human and animal cells, improved the safety and efficiency of gene therapy, avoided the risk of antibiotic resistance genes and virus integration, and is suitable for the treatment of a variety of connective tissue diseases.
Smart Images

Figure CN113994005B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to genetic engineering and can be used in biotechnology, medicine and agriculture to produce gene therapy products. Background Art
[0002] Gene therapy is an innovative approach in medicine that aims to treat hereditary and acquired diseases by delivering new genetic material into the patient's cells to compensate for or curb the function of mutant genes and / or treat genetic disorders. The end product of gene expression can be an RNA molecule or a protein molecule. However, most physiological processes in the body are related to the functional activity of protein molecules, and RNA molecules are either intermediates of protein synthesis or perform regulatory functions. Therefore, in most cases, the goal of gene therapy is to inject genes into an organism that provide transcription and further translation of protein molecules encoded by these genes. In the description of the present invention, gene expression refers to the production of protein molecules having an amino acid sequence encoded by the gene.
[0003] The genes COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1, which are included in a group of genes, play a key role in several processes in human and animal organisms. These genes are involved in the formation of the extracellular matrix of the skin and other organs, as well as in many other processes.
[0004] The main components of the dermal extracellular matrix are elastic fibers, collagen, and proteoglycans (27). Elastic fibers are composed of microfibrils rich in fibrillin, glycoproteins, elastin, and some other proteins (13). The components of the dermal extracellular matrix are interconnected by hyaluronic acid, thus forming the dermal network (27). Long collagen fibers formed by type I and type III collagen are intertwined and form an intradermal network anchored at the edge of the dermis and epidermis with type VII collagen (12).
[0005] During skin aging, which is mainly due to intrinsic mechanisms, collagen and elastic fibers in the dermis form the cellular structure (22). During aging processes caused by external factors, such as, for example, UV radiation, collagen types I, III and, most importantly, VII are lost (3; 30). In addition, long collagen fibers, elastic fibers, glycoproteins and glycosaminoglycans lose their ability to form a functional network of the dermal extracellular matrix and, instead, they form unstructured fragments in the dermis (22). These changes in the ECM are exacerbated by the elastase activity of neutrophils that migrate into the dermis due to inflammation or exposure to UV radiation (14), as well as by the activation of matrix metalloproteinases.
[0006] In addition to skin aging, which is a natural process in most cases, the dermal extracellular matrix may be involved in the pathogenesis of various diseases, the formation of which may be directly or indirectly related to the expression of different genes involved in its formation. In addition, since most of the extracellular matrix molecules are involved in various biological processes that are not limited to the skin, pathological and harmful states of the organism caused by insufficient expression of many genes may manifest as structural damage to the skin, but not limited to this tissue. For example, the collagen family is involved in the structural organization and metabolism of many tissues of the body, including cartilage, bones, tendons, skin and the whites of the eyes (sclera). It was found that individual mutations in genes encoding collagens (e.g., types I, III or V) or collagen-modifying enzymes (e.g., lysyl hydroxylases, collagenases) lead to different forms of Ehlers-Danlos syndrome, which affect the connective tissue supporting the skin, bones, blood vessels and other organs (systemic dysplasia of connective tissue). The symptoms and signs of this disease vary widely. The main symptoms include joint hypermobility, pathological scar formation and impaired wound healing, vascular weakness and velvety hyperextensible skin.
[0007] Type I collagen is the most common form of collagen in humans. Type I collagen consists of two pro-α1(I) chains and one pro-α2(I) chain. The COL1A1 gene encodes the pro-α1(I) chain and the COL1A2 gene encodes the pro-α2(I).
[0008] Mutations in the COL1A1 gene that cause infantile cortical hyperostosis, or Caffey disease, are described. This condition is characterized by edema of soft tissues (e.g., muscles), pain, and excessive formation of new bone tissue (hyperostosis). The skeletal abnormalities primarily affect the jawbones, clavicles, (collarbones), and the diaphysis of the long bones of the limbs.
[0009] Another genetic disease is brittle bone disease, which is caused by mutations in collagen genes and results in diffuse abnormal bone fragility, sometimes accompanied by sensorineural hearing loss, blue scleros, dentinogenesis imperfecta, and joint hypermobility. 90% of people with one of the main forms of the disease have mutations in the COL1A1 or COL1A2 genes. Gene therapy approaches are considered to be one of the promising directions for the treatment of this syndrome. A clinical case of experimental treatment has also been described, in which bone marrow mesenchymal stem cells expressing normal collagen genes were injected into patients with brittle bone disease, resulting in a significant therapeutic effect (18).
[0010] Type VII collagen is the main structural component of the skin, which is included in anchoring fibrils. These fibrils are located in the area that makes up the double membrane between the epidermis and the dermis. The collagen fibrils hold the two layers of skin together, connecting the epidermal basement membrane and the dermis.
[0011] The COL7A1 gene encodes type VII collagen. Three pro-alpha 1(VII) chains are wound together to form a three-chain procollagen molecule. Procollagen molecules are secreted by cells and processed by enzymes to remove extra protein fragments from the ends. Once these molecules are processed, they are arranged into long, thin bundles of mature type VII collagen.
[0012] Mutations in the COL7A1 gene cause dystrophic epidermolysis bullosa. Blisters most often occur at sites of minor injury, such as the extensor surfaces of the elbows and the dorsum of the hands and feet. Healing results in scarring, superficial epidermal cysts, and hyperpigmentation. Some patients have nail dystrophy. Extracutaneous manifestations, including urinary and gastrointestinal tract damage, external eye membranes, chronic anemia, osteoporosis, and growth retardation often occur. Patients with epidermolysis bullosa have a high risk of cancer, particularly the development of aggressive squamous cell carcinoma. According to DEBRA International, the disease affects one in every 50,000 people worldwide.
[0013] Gene therapy approaches for the treatment of epidermolysis bullosa include different experimental treatments. In several studies of COL7A1 gene mutation correction, ex vivo genome editing technology (20), microinjection of linear DNA molecules encoding the COL7A1 gene (19), cDNA integration using integrase (23), intradermal injection of lentiviral vectors (34), mutation repair technology based on TALEN nucleases (24), and injection of autologous cells, i.e., fibroblasts or keratinocytes modified with various retroviral vectors (11, 6, 7) have been successfully used. Currently, clinical trials of these approaches are at different stages of research (NCT01263379, NCT02810951).
[0014] An important step in the generation and stabilization of collagen molecules is post-translational modification, namely the hydroxylation of proline necessary for stabilizing the collagen triple helix, and the hydroxylation of lysine necessary for the subsequent covalent bonding between collagen molecules during the assembly of collagen fibers. The enzymes involved in these modification processes are prolyl 4-hydroxylase and lysyl 5-hydroxylase.
[0015] Prolyl 4-hydroxylase consists of 2 α subunits and 2 β subunits. The α subunits refer to several types, which are encoded by the P4HA1 and P4HA2 genes. Mutations in the P4HA1 gene can lead to one of the above-mentioned forms of Ehlers-Danlos syndrome. Mutations in the human P4HA1 gene have also been described, resulting in a unique pathological phenotype characterized by early joint hypermobility, joint contractures, muscle weakness and bone dysplasia as well as myopia (35). Smoking has been reported to cause inhibition of P4HA1 gene expression. The authors of this study linked this phenomenon to the induction of collagen metabolism disorders in the vascular wall of smokers, leading to an increased frequency of atherosclerosis and aneurysms (25). Mutations in the P4HA2 gene lead to myopia (21). Transcriptional inhibition of the P4HA2 gene also occurs in lymphoid cells, which may be related to the pathogenesis of neoplastic diseases (9). Changes in P4HA1 expression have been proposed as one of the methods for screening the efficacy of anti-aging cosmetic preparations from plant materials (28).
[0016] Large amounts of elastin, the protein encoded by the ELN gene, are contained together with collagen in the extracellular matrix of connective tissue. Elastin plays an important role in organs that are subjected to constant extension and compression, such as arteries, lungs, skin, tendons and various sphincters (39). Elastin and collagen fibers help organs return to their original size after extension, for example, after skin compression or bladder emptying (38). Insufficient or no cross-linking between the fibers is formed, and the formation of normal elastin forms is reduced. As a result, the tensile strength of the elastic tissue decreases, and phenomena such as thinning, muscle relaxation, and stretching occur, that is, loss of elastic properties. These disorders manifest clinically as cardiovascular changes (aneurysms and aortic ruptures, heart valve defects), frequent pneumonia and emphysema (36). If mutations in the ELN gene lead to impaired elastin synthesis in vivo, supra-aortic stenosis occurs (5). In addition, genetic engineering methods using viral vectors expressing the ELN gene have been successfully applied to modify cells for cell therapy aimed at repairing soft tissue injuries in experimental animals (16).
[0017] The PLOD1 gene encodes lysyl hydroxylase 1. This enzyme modifies lysine to produce hydroxylysine. Hydroxylysine in collagen molecules is required for the formation of cross-links between collagen fibrils. Like most genes previously associated with extracellular matrix synthesis and formation, mutations in the PLOD1 gene have been associated with the development of Ehlers-Danlos syndrome (33). There is also evidence that polymorphisms in this gene may be associated with bone density and the risk of osteoporosis (31).
[0018] The CLCA2 gene encodes a regulator of Ca channels and is expressed in various epithelial tissues (skin, corneal epithelium, esophageal, laryngeal and vaginal epithelium) (2). Experiments on rats have shown that the expression of this gene in skin keratinocytes is significantly reduced under ultraviolet irradiation (1). Researchers studying the pathogenesis of atopic dermatitis have found that this gene is necessary to protect keratinocytes from apoptosis under hyperosmotic shock (caused by water deficiency) and the lack of adhesion in the epidermis when CLCA2 is inhibited. Therefore, the CLCA2 gene is necessary for the adaptation and survival of epithelial cells under conditions of insufficient water (29).
[0019] Thus, the background of the present invention shows that mutations in the COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1 genes or insufficient expression of the proteins encoded by these genes are associated with the development of a range of diseases, including, but not limited to, inherited and acquired pathological conditions associated with disorders in the extracellular matrix organization of the skin and other organs, leading to pathological processes and deleterious conditions that fall within generally accepted standard limits but can be ameliorated and involve processes that are not directly related to the extracellular matrix. This is why the COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1 genes are included in this patent. Genetic constructs that provide expression of proteins encoded by the COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1 genes can be used to develop drugs for the prevention and treatment of different diseases and pathologies and deleterious conditions.
[0020] Furthermore, these data suggest that insufficient expression of proteins encoded by the genes COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1, included in a group of genes, is associated not only with pathological conditions but also with susceptibility to their development. Furthermore, these data suggest that insufficient expression of these proteins may not clearly appear in the form of pathologies that can be clearly described within the framework of existing clinical practice standards (e.g., using ICD codes), but at the same time lead to conditions that are detrimental to humans and animals and are associated with a worse quality of life.
[0021] Analysis of methods to enhance therapeutic gene expression has implications for the feasibility of using different gene therapy vectors.
[0022] Gene therapy vectors are divided into viral, cellular, and DNA vectors (8). Recently, gene therapy has paid more and more attention to the development of non-viral gene delivery systems, among which plasmid vectors are at the top of the list. Plasmid vectors do not have the inherent limitations of cellular and viral vectors. In target cells, they exist as episomes without integrating into the genome, and their production is relatively cheap, and there are no immune responses or side effects caused by the administration of plasmid vectors, which makes them a convenient tool for gene therapy and prevention (DNA vaccination) of genetic diseases (15).
[0023] However, limitations to the use of plasmid vectors in gene therapy are: 1) the presence of antibiotic resistance genes used to produce the construct in bacterial strains; 2) the presence of various regulatory elements represented by viral genomic sequences; and 3) the length of the therapeutic plasmid vector which determines the efficiency of vector delivery to target cells.
[0024] As is known, the European Medicines Agency considers it necessary to avoid adding antibiotic resistance marker genes to newly engineered plasmid vectors for gene therapy (Reflection paper on design modifications of gene therapy medicinal products during development / Committee for advanced therapies of 14 December 2011 EMA / CAT / GTWP / 44236 / 2009). This recommendation is mainly related to the potential risk of DNA vector penetration or horizontal antibiotic resistance gene transfer into bacterial cells present in the body that are part of the normal or opportunistic microbial flora. In addition, the presence of antibiotic resistance genes significantly increases the length of the DNA vector, which reduces its efficacy in penetrating into eukaryotic cells.
[0025] It is worth noting that antibiotic resistance genes also make a fundamental contribution to the production methods of DNA vectors. If antibiotic resistance genes are present, the strains used to produce DNA vectors are usually cultured in media containing selective antibiotics, which poses a risk of antibiotic traces in DNA vector preparations that are not fully purified. Therefore, the production of DNA vectors for gene therapy without antibiotic resistance genes is related to the production of strains, where such strains have unique characteristics, such as the ability to stably amplify therapeutic DNA vectors in media without antibiotics.
[0026] In addition, the European Medicines Agency recommends avoiding the presence of regulatory elements (promoters, enhancers, post-translational regulatory elements) that constitute genomic nucleotide sequences of various viruses in therapeutic plasmid vectors to increase the expression of therapeutic genes (Draft Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products, http: / / www.ema.europa.eu / docs / en_GB / document_library / Scientific_guideline / 2015 / 05 / WC500187020.pdf). Although these sequences can increase the expression level of therapeutic transgenes, they pose a risk of recombination with genetic material of wild-type viruses and integration into the eukaryotic genome. In addition, the relevance of overexpression of specific genes for therapy remains an unresolved issue.
[0027] The size of the therapeutic vector is also necessary. It is well known that modern plasmid vectors often have unnecessary non-functional sites that significantly increase their length (Mairhofer J, Grabherr R. / / Mol Biotechnol. 2008. 39 (2): 97-104). For example, the ampicillin resistance gene in the pBR322 series of vectors is usually composed of at least 1000 bp, accounting for more than 20% of the length of the vector itself. An inverse relationship between the length of the vector and its ability to infiltrate eukaryotic cells was observed; DNA vectors with small lengths effectively infiltrated human and animal cells. For example, in a series of experiments on transfection of HELA cells with 383-4548 bp DNA vectors, it was shown that the difference in infiltration efficacy could be as high as two orders of magnitude (100-fold difference) (10).
[0028] Therefore, for reasons of safety and maximum efficiency, preference should be given to those constructs that do not contain antibiotic resistance genes, sequences of viral origin, and whose length allows efficient penetration into eukaryotic cells when selecting DNA vectors. Strains that produce such DNA vectors in sufficient quantities for gene therapy purposes should ensure the possibility of stable DNA vector amplification using antibiotic-free nutrient media.
[0029] An example of the use of recombinant DNA vectors for gene therapy is a method for producing recombinant vectors for genetic immunity (patent number US 9550998 B2). Plasmid vectors are supercoiled plasmid DNA vectors that are used for expression of cloned genes in human and animal cells. The vector contains a replication origin, regulatory elements containing a human cytomegalovirus promoter and enhancer, and regulatory sequences from human T-cell lymphotropic virus.
[0030] The vector is accumulated in a special antibiotic-free E. coli strain by antisense complementation of the sacB gene inserted into the strain using bacteriophage. The disadvantage of this invention is the presence of regulatory elements constituting the sequences of the viral genome in the DNA vector composition.
[0031] The patents and applications described below may be considered prototypes of the present invention.
[0032] Application No. WO2001042285A2 describes a method for restoring extracellular matrix and preventing its degradation, which includes a gene therapy method and a vector expressing a gene, wherein the gene contains a sequence selected from a sequence group (SEQ1-SEQ21) expressed during the formation and maintenance of the extracellular matrix. The disadvantage of this invention is that the method for selecting sequences in the invention is not based on the physiological function of the proteins encoded by these genes, but on transcriptional analysis of different sequences. In addition, this invention does not provide a reason for the efficacy and safety of a specific vector for gene therapy.
[0033] Application No. JPH0823979A describes a gene therapy method for improving extracellular matrix formation, which includes expressing collagen and / or prolyl hydroxylase that provide biochemical reactions during collagen fiber formation. The disadvantage of this invention is the limited way of regulating extracellular matrix formation only through the hydroxylation reaction of proline in collagen molecules. Another disadvantage of this invention is the use of baculovirus vectors.
[0034] Application number WO2002094876A2 describes a method for controlling mucin expression in lung tissue using a gene therapy construct that provides CLCA2 expression. The disadvantages of this invention are the limited use of the vector and the vague safety requirements.
[0035] Therefore, in the technical context of the present invention, there is a need for the invention of an effective and safe gene therapy method that allows increasing the expression of genes involved in the formation of the extracellular matrix, taking into account direct structural molecules (such as collagen and elastin) and enzymes that provide their post-translational modification. Summary of the invention
[0036] The object of the present invention is to construct a gene therapy DNA vector in order to increase the expression level of the group of COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1 genes in human and animal organisms, said gene therapy vector combining the following characteristics:
[0037] I) The efficiency of gene therapy DNA vectors in order to increase the expression level of therapeutic genes in eukaryotic cells.
[0038] II) The possibility of safe use in gene therapy for humans and animals due to the absence of regulatory elements representing viral genomic nucleotide sequences in gene therapy DNA vectors.
[0039] III) Possibility of safe use in gene therapy in humans and animals due to the absence of antibiotic resistance genes in gene therapy DNA vectors.
[0040] IV) Producibility and constructability of gene therapy DNA vectors on an industrial scale.
[0041] Items II and III are provided in this document based on the recommendations of national regulatory authorities for gene therapy medicinal products and, in particular, the European Medicines Agency’s requirements to avoid adding antibiotic resistance marker genes to newly engineered plasmid vectors used for gene therapy (Post-reading report on design modifications of gene therapy medicinal products during development / EMA / CAT / GTWP / 44236 / 2009 of 14 December 2011, Advanced Therapies Committee) and to avoid adding viral genomes to newly engineered plasmid vectors used for gene therapy (Guideline on quality, nonclinical and clinical aspects of gene therapy medicinal products / EMA / CAT / 80183 / 2014 of 23 March 2015, Advanced Therapies Committee).
[0042] The purpose of the present invention also includes constructing strains carrying these gene therapy DNA vectors and developing and producing these gene therapy DNA vectors on an industrial scale.
[0043] The specific purpose is achieved by using a gene therapy DNA vector produced based on the gene therapy DNA vector VTvaf17, wherein the gene therapy DNA vector is used to treat diseases related to extracellular matrix formation disorders of the skin and other organs, skin structure, wound healing disorders, for preventing skin aging caused by internal and external factors, and for treating hereditary and acquired connective tissue diseases, including Ehlers-Danlos syndrome, epidermolysis bullosa, Caffey disease, osteogenesis imperfecta, pathological scarring, scarring, superficial epidermal cysts and hyperpigmentation, wherein the gene therapy DNA vector VTvaf17-COL1A1 comprises a COL1A1 therapeutic gene coding region cloned into the gene therapy DNA vector VTvaf17, having a nucleotide sequence of SEQ ID No. 1; the gene therapy DNA vector VTvaf17-COL1A2 comprises a COL1A2 therapeutic gene coding region cloned into the gene therapy DNA vector VTvaf17, having a nucleotide sequence of SEQ ID No.2; the gene therapy DNA vector VTvaf17-P4HA1 comprises the coding region of the P4HA1 therapeutic gene cloned into the gene therapy DNA vector VTvaf17, and has the nucleotide sequence SEQ ID No.3; the gene therapy DNA vector VTvaf17-P4HA2 comprises the coding region of the P4HA2 therapeutic gene cloned into the gene therapy DNA vector VTvaf17, and has the nucleotide sequence SEQ ID No.4; the gene therapy DNA vector VTvaf17-COL7A1 comprises the coding region of the COL7A1 therapeutic gene cloned into the gene therapy DNA vector VTvaf17, and has the nucleotide sequence SEQ ID No.5; the gene therapy DNA vector VTvaf17-CLCA2 comprises the coding region of the CLCA2 therapeutic gene cloned into the gene therapy DNA vector VTvaf17, and has the nucleotide sequence SEQ ID No.6; the gene therapy DNA vector VTvaf17-ELN comprises the coding region of the ELN therapeutic gene cloned into the gene therapy DNA vector VTvaf17, and has the nucleotide sequence SEQ ID No.7; The gene therapy DNA vector VTvaf17-PLOD1 comprises the coding region of the PLOD1 therapeutic gene cloned into the gene therapy DNA vector VTvaf17, and has the nucleotide sequence SEQ ID No.8.
[0044] Due to the limited size of the VTvaf17 vector portion not exceeding 3200 bp, each of the constructed gene therapy DNA vectors, namely VTvaf17-COL1A1, or VTvaf17-COL1A2, or VTvaf17-P4HA1, or VTvaf17-P4HA2, or VTvaf17-COL7A1, or VTvaf17-CLCA2, or VTvaf17-ELN, or VTvaf17-PLOD1, has the ability to effectively penetrate into human and animal cells and express the COL1A1, or COL1A2, or P4HA1, or P4HA2, or COL7A1, or CLCA2, or ELN, or PLOD1 therapeutic genes cloned therein.
[0045] Each of the constructed gene therapy DNA vectors, namely VTvaf17-COL1A1, or VTvaf17-COL1A2, or VTvaf17-P4HA1, or VTvaf17-P4HA2, or VTvaf17-COL7A1, or VTvaf17-CLCA2, or VTvaf17-ELN, or VTvaf17-PLOD1, uses the following nucleotide sequences as structural elements, which are not antibiotic resistance genes, viral genes, or regulatory elements of viral genomes, which ensures its safety for gene therapy in humans and animals.
[0046] A method for producing a gene therapy DNA vector based on the gene therapy DNA vector VTvaf17 carrying the therapeutic genes COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN, PLOD1 has also been developed, the method involving obtaining each of the gene therapy DNA vectors as follows: VTvaf17-COL1A1 or VTvaf17-COL1A2 or VTvaf17-P4HA1 or VTvaf17-P4HA 2 or VTvaf17-COL7A1 or VTvaf17-CLCA2 or VTvaf17-ELN or VTvaf17-PLOD1: The coding region of the COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN, or PLOD1 therapeutic gene is cloned into the gene therapy DNA vector VTvaf17, and the gene therapy DNA vector VTvaf17-COL1A1, SEQ ID NO: 2 and 3 are obtained respectively. ID No.1; or VTvaf17-COL1A2, SEQ ID No.2; or VTvaf17-P4HA1, SEQ ID No.3; or VTvaf17-P4HA2, SEQ ID No.4; or VTvaf17-COL7A1, SEQ ID No.5; or VTvaf17-CLCA2, SEQ ID No.6; or VTvaf17-ELN, SEQ ID No.7; or VTvaf17-PLOD1, SEQ ID No.8, wherein the coding regions of the therapeutic genes COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN, PLOD1 are obtained by isolating total RNA from human biological tissue samples, then using the obtained oligonucleotides for reverse transcription reaction and PCR amplification, and cutting the amplified products by corresponding restriction endonucleases, wherein the gene therapy DNA vector VTvaf17 is cloned by NheI and HindIII, or BamHI-KpnI, or BamHI-SalI, or SalI-EcoRI, or BamHI-EcoRI restriction sites, wherein selection is performed in the absence of antibiotics,
[0047] Among them, the following oligonucleotides generated for this purpose were used for reverse transcription reaction and PCR amplification during the production of the gene therapy DNA vector VTvaf17-COL1A1, SEQID No.1:
[0048] Col1A1_F CCAGCTAGCGTCTAGGGTCTAGACATGTTC,
[0049] Col1A1_R TATAAGCTTCTACAGGAAGCAGACAGGGCCAAC,
[0050] The amplified product was cleaved by NheI and HindIII restriction endonucleases and the coding region of the COL1A1 gene was cloned into the gene therapy DNA vector VTvaf17.
[0051] Among them, the following oligonucleotides produced for this purpose were used for reverse transcription reaction and PCR amplification during the production of the gene therapy DNA vector VTvaf17-COL1A2, SEQID No.2:
[0052] Col1A2_F CCAGCTAGCGTCTAAGTGCTAGACATGCTC,
[0053] Col1A2_RCGAAGCTTTTATTTGAAACAGACTGGGCCA,
[0054] The amplified product was cleaved by NheI and HindIII restriction endonucleases and the coding region of the COL1A2 gene was cloned into the gene therapy DNA vector VTvaf17.
[0055] Among them, the following oligonucleotides produced for this purpose were used for reverse transcription reaction and PCR amplification during the production of the gene therapy DNA vector VTvaf17-P4HA1, SEQID No.3:
[0056] P4HA1_F AGGATCCACCATGATCTGGTATATATTAATTATAGG,
[0057] P4HA1_R TTCGGTACCTATTCCAATTCTGACAACGTACAAG,
[0058] The amplified product was cleaved by BamHI and KpnI restriction endonucleases and the coding region of the P4HA1 gene was cloned into the gene therapy DNA vector VTvaf17.
[0059] Among them, the following oligonucleotides produced for this purpose were used for reverse transcription reaction and PCR amplification during the production of the gene therapy DNA vector VTvaf17-P4HA2, SEQID No.4:
[0060] P4HA2_F AGGATCACCATGAAACTCTGGGTGTCTGCA,
[0061] P4HA2_R CTTGTCGACTTAGTCAACTTCTGTTGATCCACA,
[0062] The amplified product was cleaved by BamHII and SalI restriction endonucleases and the coding region of the P4HA2 gene was cloned into the gene therapy DNA vector VTvaf17.
[0063] Among them, the following oligonucleotides produced for this purpose were used for reverse transcription reaction and PCR amplification during the production of the gene therapy DNA vector VTvaf17-COL7A1, SEQID No.5:
[0064] COL7A1_F ATCGTCGACCACCATGACGCTGCGGCTTCTGGT,
[0065] COL7A1_R ATAGAATTCAGTCCTGGGCAGTACCTGTC,
[0066] The amplified product was cut by SalI and EcoRI restriction endonucleases and the coding region of the COL7A1 gene was cloned into the gene therapy DNA vector VTvaf17.
[0067] Among them, the following oligonucleotides produced for this purpose were used for reverse transcription reaction and PCR amplification during the production of the gene therapy DNA vector VTvaf17-CLCA2, SEQID No.6:
[0068] CLCA2_F AGGATCCACCATGACCCAAAGGAGCATTGC,
[0069] CLCA2_RATAGAATTCATAATAATTTTGTTCCATTCTCTTTC,
[0070] The amplified product was cut by BamHI and EcoRI restriction endonucleases and the coding region of the CLCA2 gene was cloned into the gene therapy DNA vector VTvaf17.
[0071] Among them, the following oligonucleotides generated for this purpose were used for reverse transcription reaction and PCR amplification during the production of the gene therapy DNA vector VTvaf17-ELN, SEQ ID No. 7:
[0072] ELN_F TTTGTCGACCACCATGGCGGGTCTGACGGCGG,
[0073] ELN_R TTTTTGAATTCTCATTTTCTCTCTCCGGCCACAAGCTT,
[0074] The amplified product was cut by SalI and EcoRI restriction endonucleases and the coding region of the ELN gene was cloned into the gene therapy DNA vector VTvaf17.
[0075] Among them, the following oligonucleotides produced for this purpose were used for reverse transcription reaction and PCR amplification during the production of the gene therapy DNA vector VTvaf17-PLOD1, SEQID No.8:
[0076] PLOD1_F GGATCCACCATGCGGCCCCTGCTGCTACT,
[0077] PLOD1_R ATAGAATTCAGGGATCGACGAAGGAGACT,
[0078] The amplified product was cut by BamHII and EcoRI restriction endonucleases and the coding region of the PLOD1 gene was cloned into the gene therapy DNA vector VTvaf17.
[0079] A method for treating diseases related to disorders of extracellular matrix formation of the skin and other organs, skin structure, wound healing disorders, for preventing skin aging caused by internal and external factors, for treating hereditary and acquired connective tissue diseases including Ehlers-Danlos syndrome, epidermolysis bullosa, Caffey disease, osteogenesis imperfecta, pathological scarring, cicatrix, superficial epidermal cysts and hyperpigmentation using a gene therapy DNA vector based on VTvaf17 carrying the therapeutic genes selected from the group consisting of gene therapy DNA vectors based on VTvaf17, or several selected gene therapy DNA vectors based on VTvaf17 carrying the therapeutic genes is developed. The gene therapy DNA vector carrying the therapeutic gene is transfected into cells of organs and tissues of patients or animals; and / or the autologous cells of the patient or animal transfected with a gene therapy DNA vector based on the gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the constructed gene therapy DNA vector based on the gene therapy DNA vector VTvaf17 or several selected gene therapy DNA vectors based on the gene therapy DNA vector VTvaf17 carrying the therapeutic gene are injected into organs and tissues of the same patient or animal; and / or a gene therapy DNA vector based on the gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of constructed gene therapy DNA vectors based on the gene therapy DNA vector VTvaf17 carrying the therapeutic gene or several selected gene therapy DNA vectors based on the gene therapy DNA vector VTvaf17 carrying the therapeutic gene are injected into organs and tissues of the same patient or animal, or a combination of the indicated methods.
[0080] A method for producing a strain for constructing a gene therapy DNA vector for treating diseases related to disorders of extracellular matrix formation of the skin and other organs, skin structure, wound healing disorders, for preventing skin aging caused by internal and external factors, for treating hereditary and acquired connective tissue diseases including Ehlers-Danlos syndrome, epidermolysis bullosa, Caffey disease, osteogenesis imperfecta, pathological scarring, keloid formation, superficial epidermal cysts and hyperpigmentation has been developed, the method involving the preparation of an electrocompetent strain of the Escherichia coli strain SCS110-AF cells, and electroporated these cells with gene therapy DNA vector VTvaf17-COL1A1, or gene therapy DNA vector VTvaf17-COL1A2, or gene therapy DNA vector VTvaf17-P4HA1, or gene therapy DNA vector VTvaf17-P4HA2, or gene therapy DNA vector VTvaf17-COL7A1, or gene therapy DNA vector VTvaf17-CLCA2, or gene therapy DNA vector VTvaf17-ELN, or gene therapy DNA vector VTvaf17-PLOD1. Thereafter, the cells were poured onto an agar plate (petri dish) containing a selective medium containing yeast extract, peptone, 6% sucrose, and 10 μg / ml chloramphenicol, and as a result, the Escherichia coli strain SCS110-AF / VTvaf17-COL1A1, or the Escherichia coli strain SCS110-AF / VTvaf17-COL1A2, or the Escherichia coli strain SCS110-AF / VTvaf17-P4HA1, or the Escherichia coli strain SCS110-AF / VTvaf17-P4HA2, or the Escherichia coli strain SCS110-AF / VTvaf17-COL7A1, or the Escherichia coli strain SCS110-AF / VTvaf17-CLCA2, or the Escherichia coli strain SCS110-AF / VTvaf17-ELN, or the Escherichia coli strain SCS110-AF / VTvaf17-PLOD1 was obtained.
[0081] Claims to protect the E. coli strain SCS110-AF / VTvaf17-COL1A1, which carries the gene therapy DNA vector VTvaf17-COL1A1 for its production, allowing antibiotic-free selection during the production of the gene therapy DNA vector; or the E. coli strain SCS110-AF / VTvaf17-COL1A2, which carries the gene therapy DNA vector VTvaf17-COL1A2 for its production, allowing antibiotic-free selection during the production of the gene therapy DNA vector; or the E. coli strain SCS110-AF / VTvaf17-P4HA1 , which carries the gene therapy DNA vector VTvaf17-P4HA1 for its production, allowing for no antibiotic selection during the gene therapy DNA vector production process; or the Escherichia coli strain SCS110-AF / VTvaf17-P4HA2, which carries the gene therapy DNA vector VTvaf17-P4HA2 for its production, allowing for no antibiotic selection during the gene therapy DNA vector production process; or the Escherichia coli strain SCS110-AF / VTvaf17-COL7A1, which carries the gene therapy DNA vector VTvaf17-COL7A1 for its production, allowing for no antibiotic selection during the gene therapy DNA vector production process. The production process of the gene therapy DNA vector allows no antibiotic selection; or the Escherichia coli strain SCS110-AF / VTvaf17-CLCA2, which carries the gene therapy DNA vector VTvaf17-CLCA2 for its production, and the production process of the gene therapy DNA vector allows no antibiotic selection; or the Escherichia coli strain SCS110-AF / VTvaf17-ELN, which carries the gene therapy DNA vector VTvaf17-ELN for its production, and the production process of the gene therapy DNA vector allows no antibiotic selection; or the Escherichia coli strain SCS110-AF / VTva f17-PLOD1, which carries the gene therapy DNA vector VTvaf17-PLOD1 for its production, allowing for antibiotic-free selection during the gene therapy DNA vector production process, is used to treat diseases related to extracellular matrix formation disorders of the skin and other organs, skin structure, wound healing disorders, for the prevention of skin aging caused by internal and external factors, for the treatment of hereditary and acquired connective tissue diseases including Ehlers-Danlos syndrome, epidermolysis bullosa, Caffey disease, osteogenesis imperfecta, pathological scarring, cicatrization, superficial epidermal cysts and hyperpigmentation.
[0082] Development of a method for producing on an industrial scale a gene therapy DNA vector based on the gene therapy DNA vector VTvaf17 carrying the COL1A1, or COL1A2, or P4HA1, or P4HA2, or COL7A1, or CLCA2, or ELN, or PLOD1 therapeutic gene for the treatment of diseases associated with disorders of extracellular matrix formation of the skin and other organs, skin structure, wound healing disorders, for the prevention of skin aging caused by internal and external factors, and for the treatment of hereditary and acquired connective tissue diseases, including Ehlers -Danlos syndrome, epidermolysis bullosa, Caffey disease, osteogenesis imperfecta, pathological scarring, scarring, superficial epidermal cysts and hyperpigmentation, the method involving producing a gene therapy DNA vector VTvaf17-COL1A1, or a gene therapy DNA vector VTvaf17-COL1A2, or a gene therapy DNA vector VTvaf17-P4HA1, or a gene therapy DNA vector ДНК-вектор VTvaf17-P4HA2, or a gene therapy DNA vector VTvaf17-COL7A1, or a gene therapy DNA vector VTvaf17-P4HA2, or a gene therapy DNA vector VTvaf17-COL7A2, by: Therapy DNA vector VTvaf17-CLCA2, or gene therapy DNA vector VTvaf17-ELN, or gene therapy DNA vector VTvaf17-PLOD1: selected from Escherichia coli strain SCS110-AF / VTvaf17-COL1A1, or Escherichia coli strain SCS110-AF / VTvaf17-COL1A2, or Escherichia coli strain SCS110-AF / VTvaf17-P4HA1, or Escherichia coli strain SCS110-AF / VTvaf17-P4HA2, or Escherichia coli strain SC A culture flask containing the prepared medium is inoculated with a seed culture of S110-AF / VTvaf17-COL7A1, or E. coli strain SCS110-AF / VTvaf17-CLCA2, or E. coli strain SCS110-AF / VTvaf17-ELN, or E. coli strain SCS110-AF / VTvaf17-PLOD1, and the cell culture is then incubated on an incubator shaker and transferred to an industrial fermenter, and then cultured to the stationary phase, and then the fractions containing the target DNA product are extracted, subjected to multi-stage filtration, and purified by chromatography. BRIEF DESCRIPTION OF THE DRAWINGS
[0083] The essence of the invention is explained in the following figures, in which:
[0084] Figure 1
[0085] The structure of the gene therapy DNA vector VTvaf17 carrying a therapeutic gene selected from the group consisting of COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1 genes is shown, which constitutes a circular double-stranded DNA molecule capable of autonomously replicating in Escherichia coli cells.
[0086] Figure 1 shows the structures corresponding to:
[0087] A-Gene therapy DNA vector VTvaf17-COL1A1,
[0088] B-Gene therapy DNA vector VTvaf17-COL1A2,
[0089] C-Gene therapy DNA vector VTvaf17-P4HA1,
[0090] D-Gene therapy DNA vector VTvaf17-P4HA2,
[0091] E-Gene Therapy DNA Vector VTvaf17-COL7A1,
[0092] F-Gene therapy DNA vector VTvaf17-CLCA2,
[0093] G-Gene therapy DNA vector VTvaf17-ELN,
[0094] H-Gene therapy DNA vector VTvaf17-PLOD1.
[0095] The following structural elements of the vector are indicated by the following structure:
[0096] EF1a - The promoter region of human elongation factor EF1A contains an intrinsic enhancer contained in the first intron of the gene. It ensures efficient transcription of the recombinant gene in most human tissues.
[0097] Corresponding to COL1A1 gene ( Figure 1A )、COL1A2 gene ( Figure 1B )、P4HA1 gene( Figure 1C )、P4HA2 gene ( Figure 1D )、COL7A1 gene ( Figure 1E )、CLCA2 gene ( Figure 1F )、ELN gene( Figure 1G )、PLOD1 gene ( Figure 1H )'s coding region's reading frame of a therapeutic gene;
[0098] hGH TA - transcription terminator and polyadenylation site of human growth factor gene,
[0099] ori - origin of replication for autonomous replication with a single nucleotide substitution to increase plasmid production in most E. coli strains,
[0100] RNA out-of-RNA of the regulatory elements of the transposon Tn10 allows antibiotic-free positive selection using the E. coli strain SCS110-AF.
[0101] Unique restriction sites are marked.
[0102] Figure 2
[0103] A graph showing the accumulation of cDNA amplicons of the therapeutic gene (i.e., COL1A1 gene) in HDFa primary human dermal fibroblast cultures (ATCC PCS-201-01) before and 48 hours after transfection of these cells with the gene therapy DNA vector VTvaf17-COL1A1 is shown to facilitate the evaluation of the ability to penetrate into eukaryotic cells and the functional activity, i.e., the expression of the therapeutic gene at the mRNA level.
[0104] During the reaction, the following curve of amplicon accumulation is shown Figure 2 , corresponding to:
[0105] 1- cDNA of the COL1A1 gene in HDFa primary human skin fibroblast cultures before transfection with the DNA vector VTvaf17-COL1A1,
[0106] 2- cDNA of the COL1A1 gene in HDFa primary human skin fibroblast cultures after transfection with the DNA vector VTvaf17-COL1A1,
[0107] 3- cDNA of the B2M gene in HDFa primary human skin fibroblast cultures before transfection with the DNA vector VTvaf17-COL1A1,
[0108] 4- cDNA of the B2M gene in HDFa primary human skin fibroblast cultures after transfection with the DNA vector VTvaf17-COL1A1.
[0109] The B2M (beta-2-microglobulin) gene listed under accession number NM 004048.2 in the GenBank database was used as a reference gene.
[0110] Figure 3
[0111] A graph showing the accumulation of cDNA amplicons of the therapeutic gene (i.e., COL1A2 gene) in HDFa primary human dermal fibroblast cultures (ATCC PCS-201-01) before and 48 hours after transfection of these cells with the gene therapy DNA vector VTvaf17-COL1A2 is shown in order to evaluate the ability to penetrate into eukaryotic cells and the functional activity, i.e., the expression of the therapeutic gene at the mRNA level.
[0112] During the reaction, the following curve of amplicon accumulation is shown Figure 3 , corresponding to:
[0113] 1- cDNA of the COL1A2 gene in HDFa primary human skin fibroblast cultures before transfection with the DNA vector VTvaf17-COL1A2,
[0114] 2- cDNA of the COL1A2 gene in HDFa primary human skin fibroblast cultures after transfection with the DNA vector VTvaf17-COL1A2,
[0115] 3- cDNA of the B2M gene in HDFa primary human skin fibroblast cultures before transfection with the DNA vector VTvaf17-COL1A2,
[0116] 4- cDNA of the B2M gene in HDFa primary human skin fibroblast cultures after transfection with the DNA vector VTvaf17-COL1A2.
[0117] The B2M (beta-2-microglobulin) gene listed under accession number NM 004048.2 in the GenBank database was used as a reference gene.
[0118] Figure 4
[0119] A graph showing the accumulation of cDNA amplicons of a therapeutic gene (i.e., the P4HA1 gene) in the Hs27 primary human foreskin fibroblast cell line (ATCC CRL-1634) before and 48 hours after transfection of these cells with the gene therapy DNA vector VTvaf17-P4HA1 is shown in order to evaluate the ability to penetrate into eukaryotic cells and the functional activity, i.e., the expression of the therapeutic gene at the mRNA level.
[0120] During the reaction, the following curve of amplicon accumulation is shown Figure 4 , corresponding to:
[0121] 1- cDNA of the P4HA1 gene in the Hs27 primary human foreskin fibroblast cell line before transfection with the DNA vector VTvaf17-P4HA1,
[0122] 2- cDNA of the P4HA1 gene in the Hs27 primary human foreskin fibroblast cell line after transfection with the DNA vector VTvaf17-P4HA1,
[0123] 3- cDNA of the B2M gene in the Hs27 primary human foreskin fibroblast cell line before transfection with the DNA vector VTvaf17-P4HA1,
[0124] 4- cDNA of the B2M gene in the Hs27 human primary foreskin fibroblast cell line after transfection with the DNA vector VTvaf17-P4HA1.
[0125] The B2M (beta-2-microglobulin) gene listed under accession number NM 004048.2 in the GenBank database was used as a reference gene.
[0126] Figure 5
[0127] A graph showing the accumulation of cDNA amplicons of a therapeutic gene (i.e., the P4HA2 gene) in the Hs27 primary human foreskin fibroblast cell line (ATCC CRL-1634) before and 48 hours after transfection of these cells with the gene therapy DNA vector VTvaf17-P4HA2 is shown in order to evaluate the ability to penetrate into eukaryotic cells and the functional activity, i.e., the expression of the therapeutic gene at the mRNA level.
[0128] During the reaction, the following curve of amplicon accumulation is shown Figure 5 , corresponding to:
[0129] 1- cDNA of P4HA2 gene in Hs27 primary human foreskin fibroblast cell line before transfection with DNA vector VTvaf17-P4HA2,
[0130] 2- cDNA of the P4HA2 gene in the Hs27 primary human foreskin fibroblast cell line after transfection with the DNA vector VTvaf17-P4HA2,
[0131] 3- cDNA of the B2M gene in the Hs27 primary human foreskin fibroblast cell line before transfection with the DNA vector VTvaf17-P4HA2,
[0132] 4- cDNA of the B2M gene in the Hs27 human primary foreskin fibroblast cell line after transfection with the DNA vector VTvaf17-P4HA2.
[0133] The B2M (beta-2-microglobulin) gene listed under accession number NM 004048.2 in the GenBank database was used as a reference gene.
[0134] Figure 6
[0135] Shown in HT 297.T fibroblast culture ( CRL-7782 TM ) shows the accumulation of cDNA amplicons of the therapeutic gene (i.e., COL7A1 gene) before and 48 hours after transfection of these cells with the gene therapy DNA vector VTvaf17-COL7A1, in order to evaluate the ability to penetrate into eukaryotic cells and the functional activity, i.e., the expression of the therapeutic gene at the mRNA level.
[0136] During the reaction, the following curve of amplicon accumulation is shown Figure 6 , corresponding to:
[0137] 1- cDNA of the COL7A1 gene in HT 297.T fibroblast cultures before transfection with the DNA vector VTvaf17-COL7A1,
[0138] 2- cDNA of the COL7A1 gene in HT 297.T fibroblast cultures after transfection with the DNA vector VTvaf17-COL7A1,
[0139] 3- cDNA of the B2M gene in HT 297.T fibroblast cultures before transfection with the DNA vector VTvaf17-COL7A1,
[0140] 4- cDNA of the B2M gene in HT 297.T fibroblast cultures after transfection with the DNA vector VTvaf17-COL7A1.
[0141] The B2M (beta-2-microglobulin) gene listed under accession number NM 004048.2 in the GenBank database was used as a reference gene.
[0142] Figure 7
[0143] Shown in HT 297.T fibroblast culture ( CRL-7782 TM ) is a graph showing the accumulation of cDNA amplicons of the therapeutic gene (i.e., the CLCA2 gene) before and 48 hours after transfection of these cells with the gene therapy DNA vector VTvaf17-CLCA2, in order to evaluate the ability to penetrate into eukaryotic cells and the functional activity, i.e., the expression of the therapeutic gene at the mRNA level.
[0144] During the reaction, the following curve of amplicon accumulation is shown Figure 7 , corresponding to:
[0145] 1- cDNA of the CLCA2 gene in HT 297.T fibroblast cultures before transfection with the DNA vector VTvaf17-CLCA2,
[0146] 2- cDNA of the CLCA2 gene in HT 297.T fibroblast cultures after transfection with the DNA vector VTvaf17-CLCA2,
[0147] 3- cDNA of the B2M gene in HT 297.T fibroblast cultures before transfection with the DNA vector VTvaf17-CLCA2,
[0148] 4- cDNA of the B2M gene in HT 297.T fibroblast cultures after transfection with the DNA vector VTvaf17-CLCA2.
[0149] The B2M (beta-2-microglobulin) gene listed under accession number NM 004048.2 in the GenBank database was used as a reference gene.
[0150] Figure 8
[0151] A graph showing the accumulation of cDNA amplicons of a therapeutic gene (i.e., the ELN gene) in HEKa primary human epidermal keratinocyte cultures (ATCC PCS-200-011) before and 48 hours after transfection of these cells with the gene therapy DNA vector VTvaf17-ELN is shown to facilitate evaluation of the ability to penetrate into eukaryotic cells and functional activity, i.e., expression of the therapeutic gene at the mRNA level.
[0152] During the reaction, the following curve of amplicon accumulation is shown Figure 8 , corresponding to:
[0153] 1- cDNA of the ELN gene in HEKa primary human epidermal keratinocyte cultures before transfection with the DNA vector VTvaf17-ELN,
[0154] 2- cDNA of the ELN gene in HEKa primary human epidermal keratinocyte cultures after transfection with the DNA vector VTvaf17-ELN,
[0155] 3- cDNA of the B2M gene in HEKa primary human epidermal keratinocyte cultures before transfection with the DNA vector VTvaf17-ELN,
[0156] 4- cDNA of the B2M gene in HEKa primary human epidermal keratinocyte cultures after transfection with the DNA vector VTvaf17-ELN.
[0157] The B2M (beta-2-microglobulin) gene listed under accession number NM 004048.2 in the GenBank database was used as a reference gene.
[0158] Fig. 9
[0159] Shown in HEMa primary human epidermal melanocyte culture ( PCS-200-013 TM ) is a graph showing the accumulation of cDNA amplicons of the therapeutic gene (i.e., the PLOD1 gene) before and 48 hours after transfection of these cells with the gene therapy DNA vector VTvaf17-PLOD1, in order to evaluate the ability to penetrate into eukaryotic cells and the functional activity, i.e., the expression of the therapeutic gene at the mRNA level.
[0160] During the reaction, the following curve of amplicon accumulation is shown Fig. 9 , corresponding to:
[0161] 1- cDNA of PLOD1 gene in HEMa primary human epidermal melanocyte culture before transfection with DNA vector VTvaf17-PLOD1,
[0162] 2- cDNA of the PLOD1 gene in HEMa primary human epidermal melanocyte cultures after transfection with the DNA vector VTvaf17-PLOD1,
[0163] 3- cDNA of the B2M gene in HEMa primary human epidermal melanocyte cultures before transfection with the DNA vector VTvaf17-PLOD1,
[0164] 4- cDNA of the B2M gene in HEMa primary human epidermal melanocyte cultures after transfection with the DNA vector VTvaf17-PLOD1.
[0165] The B2M (beta-2-microglobulin) gene listed under accession number NM 004048.2 in the GenBank database was used as a reference gene.
[0166] Fig.10
[0167] A graph showing the concentration of COL1A1 protein in cell lysates in HDFa primary human dermal fibroblasts (ATCC PCS-201-01) after transfection of these cells with the DNA vector VTvaf17-COL1A1 is shown to facilitate the evaluation of functional activity, i.e. expression at the protein level based on changes in COL1A1 protein concentration in cell lysates.
[0168] Place the following components in Fig.10middle:
[0169] Culture A - HDFa human dermal fibroblast cultures transfected with an aqueous dendrimer solution without plasmid DNA (reference),
[0170] Culture B - HDFa human dermal fibroblast culture transfected with DNA vector VTvaf17,
[0171] Culture C - HDFa human dermal fibroblast culture transfected with the DNA vector VTvaf17-COL1A1.
[0172] Fig.11
[0173] A graph showing the COL1A2 protein concentration in lysates of HDFa primary human dermal fibroblast cultures (ATCC PCS-201-01) after transfection of these cells with the gene therapy DNA vector VTvaf17-COL1A2 is shown to facilitate the evaluation of functional activity (i.e., therapeutic gene expression at the protein level) and the possibility of increasing protein expression levels by gene therapy DNA vectors based on the gene therapy DNA vector VTvaf17 carrying the COL1A2 therapeutic gene.
[0174] Place the following components in Fig.11 middle:
[0175] Culture A - HDFa human dermal fibroblast cultures transfected with an aqueous dendrimer solution without plasmid DNA (reference),
[0176] Culture B - HDFa human dermal fibroblast culture transfected with DNA vector VTvaf17,
[0177] Culture C - HDFa human dermal fibroblast culture transfected with the DNA vector VTvaf17-COL1A2.
[0178] Fig.12
[0179] A graph showing the concentration of P4HA1 protein in lysates of the Hs27 primary human foreskin fibroblast cell line (ATCC CRL-1634) after transfection of these cells with the gene therapy DNA vector VTvaf17-P4HA1 is shown to facilitate the evaluation of functional activity (i.e., therapeutic gene expression at the protein level) and the possibility of increasing protein expression levels by gene therapy DNA vectors based on the gene therapy DNA vector VTvaf17 carrying the P4HA1 therapeutic gene.
[0180] Place the following components in Fig.12 middle:
[0181] Culture A - Hs27 human primary foreskin fibroblast cultures transfected with an aqueous dendrimer solution without plasmid DNA (reference),
[0182] Culture B - Hs27 primary human foreskin fibroblast culture transfected with DNA vector VTvaf17,
[0183] Culture C - Hs27 primary human foreskin fibroblast culture transfected with the DNA vector VTvaf17-P4HA1.
[0184] Fig.13
[0185] A graph showing the concentration of P4HA2 protein in lysates of the Hs27 primary human foreskin fibroblast cell line (ATCC CRL-1634) after transfection of these cells with the DNA vector VTvaf17-P4HA2 is shown to facilitate the evaluation of functional activity (i.e., therapeutic gene expression at the protein level) and the possibility of increasing protein expression levels by gene therapy DNA vectors based on the gene therapy vector VTvaf17 carrying the P4HA2 therapeutic gene.
[0186] Place the following components in Fig.13 middle:
[0187] Culture A - Hs27 human primary foreskin fibroblast cultures transfected with an aqueous dendrimer solution without plasmid DNA (reference),
[0188] Culture B - Hs27 primary human foreskin fibroblast culture transfected with DNA vector VTvaf17,
[0189] Culture C - Hs27 primary human foreskin fibroblast culture transfected with the DNA vector VTvaf17-P4HA2.
[0190] Fig.14
[0191] Shown in HT297.T human fibroblasts ( CRL-7782 TM ) after transfection of these cells with the DNA vector VTvaf17-COL7A1, in order to assess the functional activity, i.e. the expression at the protein level based on the changes in the COL7A1 protein concentration in the cell lysate.
[0192] Place the following components in Fig.14 middle:
[0193] Culture A - HT297.T human fibroblast cell culture transfected with an aqueous dendrimer solution without plasmid DNA (reference),
[0194] Culture B - HT297.T human fibroblast culture transfected with DNA vector VTvaf17,
[0195] Culture C - HT297.T human fibroblast cell culture transfected with the DNA vector VTvaf17-COL7A1.
[0196] Fig.15
[0197] Shown in HT297.T human fibroblasts ( CRL-7782 TM ) after transfection of these cells with the DNA vector VTvaf17-CLCA2, in order to assess the functional activity, i.e. the expression at the protein level based on the changes in the CLCA2 protein concentration in the cell lysate.
[0198] Place the following components in Fig.15 middle:
[0199] Culture A - HT297.T human fibroblast cell culture transfected with an aqueous dendrimer solution without plasmid DNA (reference),
[0200] Culture B - HT297.T human fibroblast culture transfected with DNA vector VTvaf17,
[0201] Culture C - HT297.T human fibroblast cell culture transfected with the DNA vector VTvaf17-CLCA2.
[0202] Fig.16
[0203] Shown is a graph of the ELN protein concentration in lysates of HEKa human epidermal keratinocyte cultures (ATCC PCS-200-011) after transfection of these cells with the DNA vector VTvaf17-ELN, in order to assess the functional activity, i.e. expression at the protein level based on changes in the ELN protein concentration in the cell lysates.
[0204] Place the following components in Fig.16 middle:
[0205] Culture A - HEKa human epidermal keratinocyte cultures transfected with an aqueous dendrimer solution without plasmid DNA (reference),
[0206] Culture B - HEKa human epidermal keratinocyte culture transfected with DNA vector VTvaf17,
[0207] Culture C - HEKa human epidermal keratinocyte culture transfected with the DNA vector VTvaf17-ELN.
[0208] Fig.17
[0209] Shown in HEMa primary human epidermal melanocyte culture ( PCS-200-013 TM ) after transfection of these cells with the DNA vector VTvaf17-PLOD1, in order to assess the functional activity, i.e. the expression at the protein level based on the changes in the PLOD1 protein concentration in the cell lysate.
[0210] Place the following components in Fig.17 middle:
[0211] Culture A - HEMa primary human epidermal melanocyte culture transfected with an aqueous dendrimer solution without plasmid DNA (reference),
[0212] Culture B - HEMa primary human epidermal melanocyte culture transfected with DNA vector VTvaf17,
[0213] Culture C - HEMa primary human epidermal melanocyte culture transfected with the DNA vector VTvaf17-PLOD1.
[0214] Fig.18
[0215] A graph showing the concentration of P4HA2 protein in skin biopsies of three patients after injection of the gene therapy DNA vector VTvaf17-P4HA2 into their skin, in order to evaluate the functional activity (i.e., expression of the therapeutic gene at the protein level) and the possibility of increasing the protein expression level using a gene therapy DNA vector based on the gene therapy vector VTvaf17 carrying the P4HA2 therapeutic gene.
[0216] Place the following components in Fig.18 middle:
[0217] P1I - Skin biopsy of patient P1 performed in the area of injection of the gene therapy DNA vector VTvaf17-P4HA2,
[0218] P1II - Skin biopsy of patient P1 in the area of injection of the gene therapy DNA vector VTvaf17 (placebo),
[0219] P1III-skin biopsy of patient P1 from intact site,
[0220] P2I - Patient P2 skin biopsy performed in the area of injection of the gene therapy DNA vector VTvaf17-P4HA2,
[0221] P2II - Patient P2 skin biopsy performed in the area of injection of the gene therapy DNA vector VTvaf17 (placebo),
[0222] P2III - Patient P2 skin biopsy from intact site,
[0223] P3I - Skin biopsy of patient P3 performed in the area of injection of the gene therapy DNA vector VTvaf17-P4HA2,
[0224] P3II - Skin biopsy of patient P3 at the injection site of the gene therapy DNA vector VTvaf17 (placebo),
[0225] P3III—Skin biopsy of patient P3 from intact site.
[0226] Fig.19
[0227] A graph showing the concentration of P4HA1 protein in skin biopsies of three patients after injection of the gene therapy DNA vector VTvaf17-P4HA1 into their skin, in order to evaluate the functional activity (i.e., expression of the therapeutic gene at the protein level) and the possibility of increasing the protein expression level using a gene therapy DNA vector based on the gene therapy vector VTvaf17 carrying the P4HA1 therapeutic gene.
[0228] Place the following components in Fig.19 middle:
[0229] P1I - Skin biopsy of patient P1 performed in the area of injection of the gene therapy DNA vector VTvaf17-P4HA1,
[0230] P1II - Skin biopsy of patient P1 in the area of injection of the gene therapy DNA vector VTvaf17 (placebo),
[0231] P1III-skin biopsy of patient P1 from intact site,
[0232] P2I - Patient P2 skin biopsy performed in the area of injection of the gene therapy DNA vector VTvaf17-P4HA1,
[0233] P2II - Patient P2 skin biopsy performed in the area of injection of the gene therapy DNA vector VTvaf17 (placebo),
[0234] P2III - Patient P2 skin biopsy from intact site,
[0235] P3I - Skin biopsy of patient P3 performed in the area of injection of the gene therapy DNA vector VTvaf17-P4HA1,
[0236] P3II - Skin biopsy of patient P3 at the injection site of the gene therapy DNA vector VTvaf17 (placebo),
[0237] P3III—Skin biopsy of patient P3 from intact site.
[0238] Fig. 20
[0239] A graph showing the concentrations of COL7A1, CLCA2, ELN and PLOD1 proteins in skin biopsy specimens of three patients after co-injection of gene therapy DNA vector VTvaf17-COL7A1, gene therapy DNA vector VTvaf17-CLCA2, gene therapy DNA vector VTvaf17-ELN and gene therapy DNA vector VTvaf17-PLOD1 into the skin of these patients, in order to facilitate the evaluation of functional activity (i.e., expression of therapeutic genes at the protein level) and the possibility of increasing protein expression levels using gene therapy DNA vector VTvaf17 carrying the COL7A1, CLCA2, ELN and PLOD1 therapeutic genes.
[0240] Place the following components in Fig. 20 middle:
[0241] P1I - skin biopsy of patient P1 performed in the area of injection of a mixture of gene therapy DNA vector VTvaf17-COL7A1, gene therapy DNA vector VTvaf17-CLCA2, gene therapy DNA vector VTvaf17-ELN and gene therapy DNA vector VTvaf17-PLOD1,
[0242] P1II - Skin biopsy of patient P1 in the area of injection of the gene therapy DNA vector VTvaf17 (placebo),
[0243] P1III-skin biopsy of patient P1 from intact site,
[0244] P2I - Patient P2 skin biopsy performed in the area of injection of a mixture of gene therapy DNA vector VTvaf17-COL7A1, gene therapy DNA vector VTvaf17-CLCA2, gene therapy DNA vector VTvaf17-ELN and gene therapy DNA vector VTvaf17-PLOD1,
[0245] P2II - Patient P2 skin biopsy performed in the area of injection of the gene therapy DNA vector VTvaf17 (placebo),
[0246] P2III - Patient P2 skin biopsy from intact site,
[0247] P3I - Patient P3 skin biopsy performed in the area of injection of a mixture of gene therapy DNA vector VTvaf17-COL7A1, gene therapy DNA vector VTvaf17-CLCA2, gene therapy DNA vector VTvaf17-ELN and gene therapy DNA vector VTvaf17-PLOD1,
[0248] P3II - Skin biopsy of patient P3 at the injection site of the gene therapy DNA vector VTvaf17 (placebo),
[0249] P3III—Skin biopsy of patient P3 from intact site.
[0250] Fig.21
[0251] Graph showing COL1A2 protein concentration in human skin biopsy samples after subcutaneous injection of autologous fibroblast cultures transfected with the gene therapy DNA vector VTvaf17-COL1A2 to illustrate the method of use of autologous cells transfected with the gene therapy DNA vector VTvaf17-COL1A2 by injection.
[0252] Place the following components in Fig.21 middle:
[0253] P1C - Skin biopsy of patient P1 performed in the area of injection of the patient's autologous fibroblast culture transfected with the gene therapy DNA vector VTvaf17-COL1A2,
[0254] P1B - skin biopsy of patient P1 performed in the area of injection of the patient's autologous fibroblasts transfected with the gene therapy DNA vector VTvaf17,
[0255] P1A - Skin biopsy of patient P1 from intact site.
[0256] Fig. 22
[0257] A graph showing the concentrations of COL1A1, COL1A2, P4HA1 and P4HA2 proteins in skin biopsy samples of three rats after co-injection into the skin of three rats with the following gene therapy DNA vectors: VTvaf17-COL7A1, VTvaf17-CLCA2, VTvaf17-P4HA1 and VTvaf17-P4HA2, in order to facilitate the evaluation of their functional activities (i.e., therapeutic gene expression at the protein level) and the possibility of increasing protein expression levels by gene therapy DNA vectors based on the gene therapy vector VTvaf17 carrying the COL1A1, COL1A2, P4HA1 and P4HA2 therapeutic genes.
[0258] Place the following components in Fig. 22 middle:
[0259] K1I - Rat K1 skin biopsy specimen at the injection site of a mixture of gene therapy DNA vectors: VTvaf17-COL1A1, VTvaf17-COL1A2, VTvaf17-P4HA1 and VTvaf17-P4HA2,
[0260] K1II - Rat K1 skin biopsy specimen at the injection site of the gene therapy DNA vector VTvaf17 (placebo),
[0261] K1III - Rat K1 skin biopsy specimen at reference intact site,
[0262] K2I - Rat K2 skin biopsy specimen at the injection site of a mixture of gene therapy DNA vectors: VTvaf17-COL1A1, VTvaf17-COL1A2, VTvaf17-P4HA1 and VTvaf17-P4HA2,
[0263] K2II - Rat K2 skin biopsy specimen at the injection site of the gene therapy DNA vector VTvaf17 (placebo),
[0264] K2III - Rat K2 skin biopsy specimen at reference intact site,
[0265] K3I - Rat K3 skin biopsy specimen at the injection site of a mixture of gene therapy DNA vectors: VTvaf17-COL1A1, VTvaf17-COL1A2, VTvaf17-P4HA1, and VTvaf17-P4HA2,
[0266] K3II - Rat K3 skin biopsy specimen at the injection site of the gene therapy DNA vector VTvaf17 (placebo),
[0267] K3III - Rat K3 skin biopsy specimen at reference intact site.
[0268] Fig.23
[0269] A graph showing the accumulation of cDNA amplicons of the ELN therapeutic gene in bovine dermal fibroblasts (ScienCell, Cat. #B2300) before and 48 hours after transfection of these cells with the DNA vector VTvaf17-ELN is shown to demonstrate the use of gene therapy DNA vectors by injection in animals.
[0270] During the reaction, the following curve of amplicon accumulation is shown Fig.23 , corresponding to:
[0271] 1- cDNA of ELN gene in bovine dermal fibroblasts before transfection with gene therapy DNA vector VTvaf17-ELN,
[0272] 2- cDNA of ELN gene in bovine dermal fibroblasts after transfection with gene therapy DNA vector VTvaf17-ELN,
[0273] 3- cDNA of ACT gene in bovine dermal fibroblasts before transfection with gene therapy DNA vector VTvaf17-ELN,
[0274] 4-cDNA of the ACT gene in bovine dermal fibroblasts after transfection with the gene therapy DNA vector VTvaf17-ELN.
[0275] The bull / cow actin gene (ACT) listed in the GenBank database under accession number AH001130.2 was used as a reference gene. DETAILED DESCRIPTION
[0276] Based on the 3165bp DNA vector VTvaf17, a gene therapy DNA vector carrying human therapeutic genes was constructed, which was designed to increase the expression level of these therapeutic genes in human and animal tissues. The method for producing each gene therapy DNA vector carrying a therapeutic gene is to clone the protein coding sequence of the therapeutic gene into the polylinker of the gene therapy DNA vector VTvaf17, and the therapeutic gene is selected from the following gene groups: human COL1A1 gene (encoding COL1A1 protein), human COL1A2 gene (encoding COL1A2 protein), human P4HA1 gene (encoding P4HA1 protein), human P4HA2 gene (encoding P4HA2 protein), human COL7A1 gene (encoding COL7A1 protein), human CLCA2 gene (encoding CLCA2 protein), human ELN gene (encoding ELN protein), human PLOD1 gene (encoding PLOD1 protein). It is well known that the ability of DNA vectors to penetrate eukaryotic cells depends mainly on the size of the vector. The smallest size DNA vector has a higher penetration ability. Therefore, it is preferred that there are no elements in the vector that do not bear the functional load but increase the size of the vector DNA at the same time. In the production process of the gene therapy DNA vector based on the gene therapy DNA vector VTvaf17 carrying a therapeutic gene selected from the group of COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1 genes, these characteristics of the DNA vector were taken into account, wherein the absence of large non-functional sequences and antibiotic resistance genes in the vector allowed the size of the produced gene therapy DNA vector VTvaf17 carrying the therapeutic gene (selected from the group of COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1 genes) to be significantly reduced in addition to the technical advantages and safe use. Therefore, the ability of the obtained gene therapy DNA vector to penetrate into eukaryotic cells is due to its small length.
[0277] Each of the following gene therapy DNA vectors: VTvaf17-COL1A1, or VTvaf17-COL1A2, or VTvaf17-P4HA1, or VTvaf17-P4HA2, or VTvaf17-COL7A1, or VTvaf17-CLCA2, or VTvaf17-ELN, or VTvaf17-PLOD1 is produced as follows: the coding region of the therapeutic gene COL1A1, or COL1A2, or P4HA1, or P4HA2, or COL7A1, or CLCA2, or ELN, or PLOD1 is cloned into the DNA vector VTvaf17, and the gene therapy DNA vector VTvaf17-COL1A1, SEQ ID No.1; or VTvaf17-COL1A2, SEQ ID No.2; or VTvaf17-P4HA1, SEQID No.3; or VTvaf17-P4HA2, SEQ ID No.4 is obtained respectively. No.4; or VTvaf17-COL7A1, SEQ ID No.5; or VTvaf17-CLCA2, SEQ ID No.6; or VTvaf17-ELN, SEQ ID No.7; or VTvaf17-PLOD1, SEQ ID No.8. The coding regions of COL1A1 gene (4410 bp), or COL1A2 gene (4116 bp), or P4HA1 gene (1607 bp), or P4HA2 gene (1605 bp), or COL7A1 gene (8838 bp), or CLCA2 gene (2833 bp), or ELN gene (2068 bp), or PLOD1 gene (2185 bp) were generated by extracting total RNA from biological normal tissue samples. The reverse transcription reaction was used to synthesize the first-strand cDNA of human COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1 genes. Amplification was performed using oligonucleotides produced for this purpose by chemical synthesis. The amplification product was cleaved by specific restriction endonucleases taking into account the optimal procedure for further cloning and cloned into the gene therapy DNA vector VTvaf17 through the BamHI, EcoRI and HindIII restriction sites located in the VTvaf17 vector polylinker. The choice of restriction sites was performed in such a way that the cloned fragment entered the reading frame of the vector VTvaf17 expression cassette, while the protein coding sequence did not contain restriction sites for the selected endonucleases.Experts in the field recognize that the methodological implementation of the generation of the gene therapy DNA vector VTvaf17-COL1A1, or VTvaf17-COL1A2, or VTvaf17-P4HA1, or VTvaf17-P4HA2, or VTvaf17-COL7A1, or VTvaf17-CLCA2, or VTvaf17-ELN, or VTvaf17-PLOD1 can vary within the selection framework of known molecular gene cloning methods, and these methods are included within the scope of the present invention. For example, different oligonucleotide sequences can be used to amplify the COL1A1, or COL1A2, or P4HA1, or P4HA2, or COL7A1, or CLCA2, or ELN, or PLOD1 genes, different restriction endonucleases or laboratory techniques (e.g., ligation-independent gene cloning).
[0278] The gene therapy DNA vector VTvaf17-COL1A1, or VTvaf17-COL1A2, or VTvaf17-P4HA1, or VTvaf17-P4HA2, or VTvaf17-COL7A1, or VTvaf17-CLCA2, or VTvaf17-ELN, or VTvaf17-PLOD1 has the nucleotide sequence SEQ ID No. 1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4, or SEQ ID No. 5, or SEQ ID No. 6, or SEQ ID No. 7, or SEQ ID No. 8, respectively. At the same time, the degeneracy of the genetic code is known to experts in the field, and this means that the scope of the present invention also includes variants of the nucleotide sequence, which differ in that the insertion, deletion or substitution of nucleotides does not lead to changes in the polypeptide sequence encoded by the therapeutic gene, and / or does not lead to the loss of functional activity of the regulatory elements of the VTvaf17 vector. At the same time, genetic polymorphisms are known to experts in the field and mean that the scope of the present invention also includes variants of the nucleotide sequences of genes from the group of COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1 genes, which also encode different variants of the amino acid sequence of the COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1 proteins, which do not differ from those listed in their functional activities under physiological conditions.
[0279] The ability to penetrate into eukaryotic cells and express functional activity, i.e., the ability to express the therapeutic gene of the obtained gene therapy DNA vector VTvaf17-COL1A1, or VTvaf17-COL1A2, or VTvaf17-P4HA1, or VTvaf17-P4HA2, or VTvaf17-COL7A1, or VTvaf17-CLCA2, or VTvaf17-ELN, or VTvaf17-PLOD1 is confirmed by injecting the obtained vector into eukaryotic cells and then analyzing the expression of specific mRNA and / or the protein product of the therapeutic gene. The presence of specific mRNA in cells injected with the gene therapy DNA vector VTvaf17-COL1A1, or VTvaf17-COL1A2, or VTvaf17-P4HA1, or VTvaf17-P4HA2, or VTvaf17-COL7A1, or VTvaf17-CLCA2, or VTvaf17-ELN, or VTvaf17-PLOD1 shows the ability of the obtained vector to penetrate into eukaryotic cells and express the mRNA of the therapeutic gene. In addition, experts in the field know that the presence of mRNA gene is a mandatory condition, but not a proof of the translation of the protein encoded by the therapeutic gene. Therefore, in order to confirm the property of the gene therapy DNA vector VTvaf17-COL1A1, or VTvaf17-COL1A2, or VTvaf17-P4HA1, or VTvaf17-P4HA2, or VTvaf17-COL7A1, or VTvaf17-CLCA2, or VTvaf17-ELN, or VTvaf17-PLOD1 in expressing therapeutic genes at the protein level in eukaryotic cells injected with the gene therapy DNA vector, the concentration of proteins encoded by the therapeutic genes was analyzed using an immunological method. The presence of COL1A1, or COL1A2, or P4HA1, or P4HA2, or COL7A1, or CLCA2, or ELN, or PLOD1 protein confirms the efficacy of therapeutic gene expression in eukaryotic cells, and the possibility of increasing protein concentration using a gene therapy DNA vector based on the gene therapy DNA vector VTvaf17 carrying a therapeutic gene (selected from the group of COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1 genes).
[0280] Therefore, in order to confirm the expression efficacy of gene therapy DNA vectors VTvaf17-COL1A1 carrying a therapeutic gene, namely, COL1A1 gene, gene therapy DNA vectors VTvaf17-COL1A2 carrying a therapeutic gene, namely, COL1A2 gene, gene therapy DNA vectors VTvaf17-P4HA1 carrying a therapeutic gene, namely, P4HA2 gene, gene therapy DNA vectors VTvaf17-P4HA2 carrying a therapeutic gene, namely, COL7A1 gene, gene therapy DNA vectors VTvaf17-COL7A1 carrying a therapeutic gene, namely, CLCA2 gene, gene therapy DNA vectors VTvaf17-CLCA2 carrying a therapeutic gene, namely, ELN gene, gene therapy DNA vectors VTvaf17-ELN carrying a therapeutic gene, and gene therapy DNA vectors VTvaf17-PLOD1 carrying a therapeutic gene, the following method was used:
[0281] A) Real-time PCR, i.e., changes in mRNA accumulation of therapeutic genes in human and animal cell lysates after transfection of different human and animal cell lines with gene therapy DNA vectors,
[0282] B) ELISA, which quantitatively measures changes in levels of therapeutic proteins in human cell lysates after transfection of different human cell lines with gene therapy DNA vectors,
[0283] C) Enzyme-linked immunosorbent assay, which is the quantitative level change of therapeutic protein in the supernatant of human and animal tissue biopsy specimens after injection of gene therapy DNA vector into these tissues,
[0284] D) ELISA, which quantifies changes in levels of therapeutic protein in the supernatants of human tissue biopsies following injection of these tissues with that person's autologous cells transfected with a gene therapy DNA vector.
[0285] In order to confirm the feasibility of using the constructed gene therapy DNA vectors VTvaf17-COL1A1 carrying the therapeutic gene, i.e., COL1A1 gene, VTvaf17-COL1A2 carrying the therapeutic gene, i.e., COL1A2 gene, VTvaf17-P4HA1 carrying the therapeutic gene, i.e., NP4HA2 gene, VTvaf17-P4HA2 carrying the therapeutic gene, i.e., COL7A1 gene, VTvaf17-COL7A1 carrying the therapeutic gene, i.e., CLCA2 gene, VTvaf17-CLCA2 carrying the therapeutic gene, i.e., ELN gene, VTvaf17-ELN carrying the therapeutic gene, and VTvaf17-PLOD1 carrying the therapeutic gene, the following were performed:
[0286] A) Transfection of different human and animal cell lines with gene therapy DNA vectors,
[0287] B) Injecting gene therapy DNA vectors into different human and animal tissues,
[0288] C) Injecting a mixture of gene therapy DNA vectors into human and animal tissues,
[0289] D) Injection of autologous cells transfected with gene therapy DNA vectors into human tissues.
[0290] As demonstrated by the lack of regions homologous to viral genomes and antibiotic resistance genes in the nucleotide sequences of gene therapy DNA vector VTvaf17-COL1A1, or gene therapy DNA vector VTvaf17-COL1A2, or gene therapy DNA vector VTvaf17-P4HA1, or gene therapy DNA vector VTvaf17-P4HA2, or gene therapy DNA vector VTvaf17-COL7A1, or gene therapy DNA vector VTvaf17-CLCA2, or gene therapy DNA vector VTvaf17-ELN, or gene therapy DNA vector VTvaf17-PLOD1 (SEQ ID No.1, or SEQ ID No.2, or SEQ ID No.3, or SEQ ID No.4, or SEQ ID No.5, or SEQ ID No.6, or SEQ ID No.7, or SEQ ID No.8, respectively), these methods of use lack the potential risks of gene therapy for humans and animals due to the lack of regulatory elements constituting the nucleotide sequence of the viral genome and the lack of antibiotic resistance genes in the gene therapy DNA vectors.
[0291] It is known to those skilled in the art that the use of antibiotic resistance genes in gene therapy DNA vectors is achieved by increasing bacterial biomass in a nutrient medium containing selective antibiotics to obtain a preparative amount of these vectors. Within the framework of the present invention, in order to ensure the safe use of the gene therapy DNA vector VTvaf17 carrying the COL1A1, or COL1A2, or P4HA1, or P4HA2, or COL7A1, or CLCA2, or ELN, or PLOD1 therapeutic gene, it is not possible to use a selective nutrient medium containing antibiotics. A method for obtaining strains for the production of these gene therapy vectors based on the Escherichia coli strain SCS110-AF is proposed as a technical solution for obtaining the gene therapy DNA vector VTvaf17 carrying a therapeutic gene (selected from the group of COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1 genes) in order to facilitate the expansion of the production of gene therapy vectors on an industrial scale. E. coli strain SCS110-AF / VTvaf17-COL1A1, or E. coli strain SCS110-AF / VTvaf17-COL1A2, or E. coli strain SCS110-AF / VTvaf17-P4HA1, or E. coli strain SCS110-AF / VTvaf17-P4HA2, or E. coli strain SCS110-AF / VTvaf17-COL7A1, or E. coli strain SCS110-AF / VTvaf17-CLCA2, or E. coli strain SCS110-AF / VTvaf17-ELN, or E. coli strain SCS110-AF / VTvaf17- The method for producing 17-PLOD1 involves the production of competent cells of the Escherichia coli strain SCS110-AF, into which the gene therapy DNA vector VTvaf17-COL1A1, or the DNA vector VTvaf17-COL1A2, or the DNA vector VTvaf17-P4HA1, or the DNA vector VTvaf17-P4HA2, or the DNA vector VTvaf17-COL7A1, or the DNA vector VTvaf17-CLCA2, or the DNA vector VTvaf17-ELN, or the DNA vector VTvaf17-PLOD1 are injected, respectively, using a transformation (electroporation) method well known to experts in the field.The obtained Escherichia coli strain SCS110-AF / VTvaf17-COL1A1, or Escherichia coli strain SCS110-AF / VTvaf17-COL1A2, or Escherichia coli strain SCS110-AF / VTvaf17-P4HA1, or Escherichia coli strain SCS110-AF / VTvaf17-P4HA2, or Escherichia coli strain SCS110-AF / VTvaf17-COL7A1, or Escherichia coli strain SCS110-AF / VTvaf17-CLCA2, or Escherichia coli strain strain SCS110-AF / VTvaf17-ELN, or E. coli strain SCS110-AF / VTvaf17-PLOD1 was used to produce the gene therapy DNA vector VTvaf17-COL1A1, or VTvaf17-COL1A2, or VTvaf17-P4HA1, or VTvaf17-P4HA2, or VTvaf17-COL7A1, or VTvaf17-CLCA2, or VTvaf17-ELN, or VTvaf17-PLOD1, respectively, allowing the use of antibiotic-free culture medium.
[0292] To confirm the construction of E. coli strain SCS110-AF / VTvaf17-COL1A1, or E. coli strain SCS110-AF / VTvaf17-COL1A2, or E. coli strain SCS110-AF / VTvaf17-P4HA1, or E. coli strain SCS110-AF / VTvaf17-P4HA2, or E. coli strain SCS110-AF / VTvaf17-COL7A1, or E. coli strain SCS110-AF / VTvaf17-CLCA2, or E. coli strain SCS110-AF / VTvaf17-ELN, or E. coli strain SCS110-AF / VTvaf17-PLOD1, transformation, selection, subsequent biomass growth and extraction of plasmid DNA were performed.
[0293] In order to confirm the manufacturability, constructability and industrial scale of the gene therapy DNA vector VTvaf17-COL1A1 carrying the therapeutic gene, i.e., the COL1A1 gene, or the gene therapy DNA vector VTvaf17-COL1A2 carrying the therapeutic gene, i.e., the P4HA1 gene, VTvaf17-P4HA1, or the gene therapy DNA vector VTvaf17-P4HA2 carrying the therapeutic gene, i.e., the NP4HA2 gene, or the gene therapy DNA vector VTvaf17-COL7A1 carrying the therapeutic gene, i.e., the CLCA2 gene, VTvaf17-CLCA2, or the gene therapy DNA vector VTvaf17-ELN carrying the therapeutic gene, i.e., the PLOD1 gene, VTvaf17-PLOD1 The production was expanded on an industrial scale by using E. coli strains SCS110-AF / VTvaf17-COL1A1, or E. coli strains SCS110-AF / VTvaf17-COL1A2, or E. coli strains SCS110-AF / VTvaf17-COL1A2, or E. coli strains SCS110-AF / VTvaf17-COL1A1 ...1, or E. coli strains SCS110-AF / VTvaf17-COL1A2, or E. coli strains SCS110-AF / VT 10-AF / VTvaf17-P4HA1, or Escherichia coli strain SCS110-AF / VTvaf17-P4HA2, or Escherichia coli strain SCS110-AF / VTvaf17-COL7A1, or Escherichia coli strain SCS110-AF / VTvaf17-CLCA2, or Escherichia coli strain SCS110-AF / VTvaf17-ELN, or Escherichia coli strain SCS110-AF / VTvaf17-PLOD1 were fermented.
[0294] The method for scaling up the production of bacterial masses to industrial scale for isolating a gene therapy DNA vector VTvaf17 carrying a therapeutic gene (selected from the group consisting of COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1 genes) involves incubating Escherichia coli strain SCS110-AF / VTvaf17-COL1A1, or Escherichia coli strain SCS110-AF / VTvaf17-COL1A1, in an antibiotic-free nutrient medium that provides suitable biomass accumulation dynamics. 1A2, or seed culture of E. coli strain SCS110-AF / VTvaf17-P4HA1, or E. coli strain SCS110-AF / VTvaf17-P4HA2, or E. coli strain SCS110-AF / VTvaf17-COL7A1, or E. coli strain SCS110-AF / VTvaf17-CLCA2, or E. coli SCS110-AF / VTvaf17-ELN, or E. coli SCS110-AF / VTvaf17-PLOD1. After reaching a sufficient amount of biomass in the logarithmic growth phase, the bacterial culture is transferred to an industrial fermenter and then cultured to the stationary phase, and then the fractions containing the therapeutic DNA product (i.e., gene therapy DNA vector VTvaf17-COL1A1, or DNA vector VTvaf17-COL1A2, or DNA vector VTvaf17-P4HA1, or DNA vector VTvaf17-P4HA2, or DNA vector VTvaf17-COL7A1, or DNA vector VTvaf17-CLCA2, or DNA vector VTvaf17-ELN, or DNA vector VTvaf17-PLOD1) are extracted, multi-stage filtered, and purified by a chromatographic method. Experts in the field know that the culture conditions of the strains, the composition of the nutrient medium (except for the absence of antibiotics), the equipment used, and the DNA purification method can vary within the framework of the standard operating procedures of a specific production line, but the use of E. coli strain SCS110-AF / VTvaf17-COL1A1, or E. coli strain SCS110-AF / VTvaf17-COL1A2, or E. coli strain SCS110-AF / VTvaf17-P4HA1, or E. coli strain Known methods for the expansion, industrial production, and purification of DNA vectors of SCS110-AF / VTvaf17-P4HA2, or E. coli strain SCS110-AF / VTvaf17-COL7A1, or E. coli strain SCS110-AF / VTvaf17-CLCA2, or E. coli strain SCS110-AF / VTvaf17-ELN, or E. coli strain SCS110-AF / VTvaf17-PLOD1 fall within the scope of the present invention.
[0295] The nature of the present invention is explained in the following examples.
[0296] Example 1.
[0297] Generation of the gene therapy DNA vector VTvaf17-COL1A1 carrying the therapeutic gene, namely the COL1A1 gene.
[0298] The gene therapy DNA vector VTvaf17-COL1A1 was constructed by cloning the COL1A1 gene coding region (4410 bp) into the 3165 bp DNA vector VTvaf17 by NheI and HindIII restriction sites. Total RNA was isolated from biological human tissue samples and then reverse transcribed using the commercial kit Mint-2 (Evrogen, Russia), and the following oligonucleotides and commercially available kits were used. High-fidelity DNA polymerase (New England Biolabs, USA) was used for PCR amplification to obtain the COL1A1 gene coding region (4410 bp):
[0299] Col1A1_F CCAGCTAGCGTCTAGGGTCTAGACATGTTC,
[0300] Col1A1_R TATAAGCTTCTACAGGAAGCAGACAGGGCCAAC.
[0301] The gene therapy DNA vector VTvaf17 was constructed by integrating six fragments of DNA derived from different sources;
[0302] (a) The replication origin was generated by PCR amplification of a region of the commercially available plasmid pBR322 with a point mutation;
[0303] (b) The EF1a promoter region was generated by PCR amplification of the locus from human genomic DNA;
[0304] (c) hGH-TA transcription terminator was generated by PCR amplification of the human genomic DNA site;
[0305] (d) The RNA-OUT regulatory site of transposon Tn10 was synthesized by oligonucleotides;
[0306] (e) The kanamycin resistance gene was generated by PCR amplification of a site from the commercially available human plasmid pET-28;
[0307] (f) The polylinker is generated by annealing two synthetic oligonucleotides.
[0308] According to the manufacturer's instructions, use a commercially available kit High-fidelity DNA polymerase (New England Biolabs, USA) is used for PCR amplification. These fragments have overlapping regions, allowing them to merge in subsequent PCR amplification. Fragments (a) and (b) are integrated using oligonucleotides Ori-F and EF1-R, and fragments (c), (d) and (e) are integrated using oligonucleotides hGH-F and Kan-R. Afterwards, the fragments produced are integrated by restriction with sites BamHI and NcoI, followed by connection. This forms a plasmid that still lacks a polylinker. In order to add it, the plasmid is cut by BamHI and EcoRI sites and then connected to fragment (f). Therefore, a 4182bp kanamycin resistance gene vector is constructed, which carries SpeI restriction sites on the flanks. The gene is then cut with the SpeI restriction site, and the remaining fragments are connected to themselves. This forms a recombinant 3165bp gene therapy DNA vector VTvaf17, and allows antibiotic-free selection.
[0309] The amplified product of the COL1A1 gene coding region and the DNA vector VTvaf17 were cleaved by NheI and HindIII restriction endonucleases (New England Biolabs, USA).
[0310] This forms a 7563 bp DNA vector VTvaf17-COL1A1 having a nucleotide sequence of SEQ ID No. 1, and a general structure of Figure 1A shown.
[0311] Example 2.
[0312] Generation of the gene therapy DNA vector VTvaf17-COL1A2 carrying the therapeutic gene, namely the COL1A2 gene.
[0313] The coding region (4116 bp) of the COL1A2 gene was cloned into the 3165 bp DNA vector VTvaf17 by NheI and HindIII restriction sites to construct the gene therapy DNA vector VTvaf17-COL1A2. Total RNA was isolated from biological human tissue samples and then reverse transcribed using the commercial kit Mint-2 (Evrogen, Russia) and the following oligonucleotides and commercially available kits were used. High-fidelity DNA polymerase (New England Biolabs, USA) was used for PCR amplification to obtain the COL1A2 gene coding region (4116 bp):
[0314] Col1A2_F CCAGCTAGCGTCTAAGTGCTAGACATGCTC,
[0315] Col1A2_RCGAAGCTTTTATTTGAAACAGACTGGGCCA;
[0316] The amplified product and the DNA vector VTvaf17 were cleaved by restriction endonucleases NheI and HindIII (New England Biolabs, USA).
[0317] This formed a 7269 bp DNA vector VTvaf17-COL1A2 having the nucleotide sequence SEQ ID No. 2 and a general structure as Figure 1B shown.
[0318] The gene therapy DNA vector VTvaf17 was constructed as described in Example 1.
[0319] Example 3.
[0320] Generation of the gene therapy DNA vector VTvaf17-P4HA1 carrying the therapeutic gene, namely the human P4HA1 gene.
[0321] The gene therapy DNA vector VTvaf17-P4HA1 was constructed by cloning the P4HA1 gene coding region (1607 bp) into the 3165 bp DNA vector VTvaf17 via BamHI and KpnI restriction sites. Total RNA was isolated from biological human tissue samples and then reverse transcribed using the commercial kit Mint-2 (Evrogen, Russia) and the following oligonucleotides and commercially available kits were used. High-fidelity DNA polymerase (New England Biolabs, USA) was used for PCR amplification to obtain the P4HA1 gene coding region (1607 bp):
[0322] P4HA1_F AGGATCCACCATGATCTGGTATATATTAATTATAGG,
[0323] P4HA1_R TTCGGTACCTATTCCAATTCTGACAACGTACAAG;
[0324] The amplified product and the DNA vector VTvaf17 were cleaved by BamHI and KpnI restriction endonucleases (New England Biolabs, USA).
[0325] This formed a 4754 bp DNA vector VTvaf17-P4HA1 having the nucleotide sequence SEQ ID No. 3 and a general structure as Figure 1C shown.
[0326] The gene therapy DNA vector VTvaf17 was constructed as described in Example 1.
[0327] Example 4.
[0328] Generation of the gene therapy DNA vector VTvaf17-P4HA2 carrying the therapeutic gene, namely the P4HA2 gene.
[0329] The gene therapy DNA vector VTvaf17-P4HA2 was constructed by cloning the P4HA2 gene coding region (1605 bp) into the 3165 bp DNA vector VTvaf17 via the BamHII and SalI restriction sites. Total RNA was isolated from biological human tissue samples and then reverse transcribed using the commercial kit Mint-2 (Evrogen), and the following oligonucleotides and commercially available kits were used. High-fidelity DNA polymerase (New England Biolabs, USA) was used for PCR amplification to obtain the P4HA2 gene coding region (1605 bp):
[0330] P4HA2_F AGGATCACCATGAAACTCTGGGTGTCTGCA,
[0331] P4HA2_R CTTGTCGACTTAGTCAACTTCTGTTGATCCACA;
[0332] The amplified product and the DNA vector VTvaf17 were cleaved by BamHII and SalI restriction endonucleases (New England Biolabs, USA).
[0333] This formed a 4704 bp DNA vector VTvaf17-P4HA2 having the nucleotide sequence SEQ ID No. 4, and its general structure is as follows Figure 1D shown.
[0334] The gene therapy DNA vector VTvaf17 was constructed as described in Example 1.
[0335] Example 5.
[0336] The gene therapy DNA vector VTvaf17-COL7A1 carries the therapeutic gene, namely the COL7A1 gene.
[0337] The gene therapy DNA vector VTvaf17-COL7A1 was constructed by cloning the COL7A1 gene coding region (8838 bp) into the 3165 bp DNA vector VTvaf17 via the SalI and EcoRI restriction sites. Total RNA was isolated from biological human tissue samples and then reverse transcribed using the commercial kit Mint-2 (Evrogen, Russia) and the following oligonucleotides and commercially available kits were used. High-fidelity DNA polymerase (New England Biolabs, USA) was used for PCR amplification to obtain the COL7A1 gene coding region (8838 bp):
[0338] COL7A1_F ATCGTCGACCACCATGACGCTGCGGCTTCTGGT,
[0339] COL7A1_RATAGAATTCAGTCCTGGGCAGTACCTGTC;
[0340] The amplified product and the DNA vector VTvaf17 were cleaved by restriction endonucleases SalI and EcoRI (New England Biolabs, USA).
[0341] This formed a DNA vector VTvaf17-COL7A1 of 11990 bp having the nucleotide sequence SEQ ID No. 5, and its general structure is as follows Figure 1E shown.
[0342] The gene therapy DNA vector VTvaf17 was constructed as described in Example 1.
[0343] Example 6.
[0344] Generation of the gene therapy DNA vector VTvaf17-CLCA2 carrying the therapeutic gene, namely the human CLCA2 gene.
[0345] The gene therapy DNA vector VTvaf17-CLCA2 was constructed by cloning the 2833 bp coding region of the CLCA2 gene into the 3165 bp DNA vector VTvaf17 through the BamHI and EcoRI restriction sites. Total RNA was isolated from biological human tissue samples and then reverse transcribed using the commercial kit Mint-2 (Evrogen, Russia) and the following oligonucleotides and commercially available kits were used. High-fidelity DNA polymerase (New England Biolabs, USA) was used for PCR amplification to obtain the CLCA2 gene coding region (2833 bp):
[0346] CLCA2_F AGGATCCACCATGACCCAAAGGAGCATTGC,
[0347] CLCA2_R ATAGAATTCATAATAATTTTGTTCCATTCTCTTTC;
[0348] The amplified product and the DNA vector VTvaf17 were cleaved by restriction endonucleases BamHI and EcoRI (New England Biolabs, USA).
[0349] This formed a 5974 bp DNA vector VTvaf17-CLCA2 having the nucleotide sequence SEQ ID No. 6 and a general structure as Figure 1F shown.
[0350] The gene therapy DNA vector VTvaf17 was constructed as described in Example 1.
[0351] Example 7.
[0352] Generation of the gene therapy DNA vector VTvaf17-ELN carrying the therapeutic gene, ELN gene.
[0353] The gene therapy DNA vector VTvaf17-ELN was constructed by cloning the ELN gene coding region (2068 bp) into the 3165 bp DNA vector VTvaf17 via the SalI and EcoRI restriction sites. Total RNA was isolated from biological human tissue samples and then reverse transcribed using the commercial kit Mint-2 (Evrogen), and the following oligonucleotides and commercially available kits were used. High-fidelity DNA polymerase (New England Biolabs, USA) was used for PCR amplification to obtain the coding region of the ELN gene (2068 bp):
[0354] ELN_F TTTGTCGACCACCATGGCGGGTCTGACGGCGG,
[0355] ELN_R TTTTTGAATTCTCATTTTCTCTCTCCGGCCACAAGCTT;
[0356] The amplified product and the DNA vector VTvaf17 were cleaved by restriction endonucleases SalI and EcoRI (New England Biolabs, USA).
[0357] This formed a 5257 bp DNA vector VTvaf17-ELN having the nucleotide sequence SEQ ID No. 7 and a general structure as Figure 1G shown.
[0358] The gene therapy DNA vector VTvaf17 was constructed as described in Example 1.
[0359] Example 8.
[0360] Generation of the gene therapy DNA vector VTvaf17-PLOD1 carrying the therapeutic gene, namely the PLOD1 gene.
[0361] The gene therapy DNA vector VTvaf17-PLOD1 was constructed by cloning the 2185 bp coding region of the PLOD1 gene into the 3165 bp DNA vector VTvaf17 via the BamHII and EcoRI restriction sites. Total RNA was isolated from biological human tissue samples and then reverse transcribed using the commercial kit Mint-2 (Evrogen), and the following oligonucleotides and commercially available kits were used. High-fidelity DNA polymerase (New England Biolabs, USA) was used for PCR amplification to obtain the PLOD1 gene coding region (2185 bp):
[0362] PLOD1_F GGATCCACCATGCGGCCCCTGCTGCTACT,
[0363] PLOD1_RATAGAATTCAGGGATCGACGAAGGAGACT;
[0364] The amplified product and the DNA vector VTvaf17 were cleaved by restriction endonucleases BamHII and EcoRI (New England Biolabs, USA).
[0365] This formed a 5326 bp DNA vector VTvaf17-PLOD1 having the nucleotide sequence SEQ ID No. 8 and a general structure as Figure 1H shown.
[0366] The gene therapy DNA vector VTvaf17 was constructed as described in Example 1.
[0367] Example 9.
[0368] The ability of the gene therapy DNA vector VTvaf17-COL1A1 carrying the therapeutic gene, namely the COL1A1 gene, to penetrate into eukaryotic cells and evidence of its functional activity at the level of therapeutic gene mRNA expression This example also demonstrates the feasibility of using a gene therapy DNA vector carrying a therapeutic gene.
[0369] Changes in the accumulation of COL1A1 therapeutic gene mRNA were evaluated in HDFa primary human dermal fibroblast cultures (ATCC PCS-201-01) 48 h after transfection with the gene therapy DNA vector VTvaf17-COL1A1 carrying the human COL1A1 gene. The amount of mRNA was determined dynamically by the accumulation of cDNA amplicons in real-time PCR.
[0370] HDFa primary human dermal fibroblast cultures were used to evaluate changes in therapeutic COL1A1 mRNA accumulation. Serum-free fibroblast growth kit ( PCS-201-040), HDFa cell cultures were cultured under standard conditions (37°C, 5% CO2). During the culture process, the growth medium was replaced every 48 hours.
[0371] To achieve 90% confluence, cells were seeded into 24-well plates at 5x10 cells per well 24 hours before transfection. 4 Cells. According to the manufacturer's recommendations, Lipofectamine 3000 (Thermfisher Scientificial, USA) was used to transfect with the gene therapy DNA vector VTvaf17-COL1A1 expressing the human COL1A1 gene. In test tube 1, 1 μL of DNA vector VTvaf17-COL1A1 solution (concentration 500ng / μL) and 1 μL of reagent P3000 were added to 25 μL of culture medium Opti-MEM (Gibco, USA). The preparation was mixed by gentle shaking. In test tube 2, 1 μL of Lipofectamine 3000 solution was added to 25 μL of culture medium Opti-MEM (Gibco, USA). The preparation was mixed by gentle shaking. The contents from test tube 1 were added to the contents of test tube 2, and the mixture was incubated at room temperature for 5 minutes. The resulting solution was added dropwise to the cells in a volume of 40 μl.
[0372] HDFa cells transfected with a gene therapy DNA vector VTvaf17 lacking an inserted therapeutic gene (cDNA of the COL1A1 gene is not shown in the figure before and after transfection with a gene therapy DNA vector VTvaf17 lacking an inserted therapeutic gene) were used as a reference. The reference vector VTvaf17 for transfection was prepared as described above.
[0373] Total RNA was extracted from HDFa cells using Trizol reagent (Invitrogen, USA) according to the manufacturer's recommendations. 1 ml of Trizol reagent was added to the wells containing cells, homogenized, and heated at 65°C for 5 minutes. The samples were centrifuged at 14000g for 10 minutes and then heated again at 65°C for 10 minutes. Then, 200 μL of chloroform was added, and the mixture was gently stirred and centrifuged at 14000g for 10 minutes. The aqueous phase was then separated and mixed with 1 / 10 volume of 3M sodium acetate (pH 5.2) and an equal volume of isopropanol. The samples were incubated at -20°C for 10 minutes and then centrifuged at 14000g for 10 minutes. The precipitated RNA was rinsed in 1 ml of 70% ethanol, air-dried, and dissolved in 10 μL of nuclease-free water. The expression level of COL1A1 mRNA after transfection was determined by evaluating the accumulation dynamics of cDNA amplicons by real-time PCR. For the generation and amplification of cDNA specific for the human COL1A1 gene, the following COL1A1_SF and COL1A1_SR oligonucleotides were used:
[0374] Col1A1_SFTGACCTCAAGATGTGCCACT,
[0375] Col1A1_SR CAGACATGCCTCTTGTCCTTG
[0376] The length of the amplified product was 195 bp.
[0377] Reverse transcription reaction and PCR amplification were performed using the SYBR GreenQuantitect RT-PCR kit (Qiagen, USA) for real-time PCR. The reaction was carried out in a volume of 20 μL, containing: 25 μL of QuantiTect SYBR GreenRT-PCRMaster Mix, 2.5 mM magnesium chloride, 0.5 μm of each primer and 5 μL RNA. CFX96 amplification instrument (Bio-Rad, USA) was used under the following conditions: reverse transcription at 42 ° C for 30 min, denaturation at 98 ° C for 15 min, denaturation at 94 ° C for 15 s, annealing at 60 ° C for 30 s, extension at 72 ° C for 30 s, for a total of 40 cycles. The B2M (β-2-microglobulin) gene listed in the GenBank database with number NM 004048.2 was used as a reference gene. The positive control included an amplicon from PCR on a matrix, and the matrix was represented by a plasmid containing COL1A1 and B2M gene cDNA sequences and at a known concentration. The negative control included deionized water. Bio-Rad CFX Manager 2.1 software (Bio-Rad, USA) was used to perform real-time quantification of the accumulation dynamics of COL1A1 and B2M gene cDNA amplicons. Figure 2 shown.
[0378] Figure 2 The results also demonstrate the feasibility of using the gene therapy DNA vector VTvaf17-COL1A1 to increase the expression level of the COL1A1 gene in eukaryotic cells.
[0379] Example 10.
[0380] The ability of the gene therapy DNA vector VTvaf17-COL1A2 carrying the therapeutic gene, namely the COL1A2 gene, to penetrate into eukaryotic cells and evidence of its functional activity at the level of therapeutic gene mRNA expression. This example also demonstrates the feasibility of using a gene therapy DNA vector carrying a therapeutic gene.
[0381] Changes in the accumulation of COL1A2 therapeutic gene mRNA were evaluated in HDFa primary human dermal fibroblasts (ATCC PCS-201-01) 48 h after transfection with the gene therapy DNA vector VTvaf17-COL1A2 carrying the human COL1A2 gene. The amount of mRNA was determined dynamically by the accumulation of cDNA amplicons in real-time PCR.
[0382] In serum-free fibroblast growth kit ( HDFa primary human dermal fibroblast cultures were cultured in standard conditions (37°C, 5% CO2) in a 4% CO2 incubator (PCS-201-040). To achieve 90% confluence, cells were seeded into 24-well plates at 5x10 cells per well 24 hours before transfection. 4The amount of cells was 100 cells / mL. Lipofectamine 3000 (Thermo Fisher Scientific, USA) was used as a transfection reagent. According to the procedure described in Example 9, the gene therapy DNA vector VTvaf17-COL1A2 expressing the human COL1A2 gene was used for transfection. The B2M (β-2-microglobulin) gene listed in the GenBank database with the number NM 004048.2 was used as a reference gene. HDFa cell cultures transfected with the gene therapy DNA vector VTvaf17 lacking a therapeutic gene (the cDN of the COL1A2 gene is not shown in the figure before and after transfection with the gene therapy DNA vector VTvaf17 lacking an inserted therapeutic gene) were used as a reference. RNA isolation, reverse transcription reaction, and real-time PCR were performed as described in Example 9, except that oligonucleotides with different sequences from Example 9 were used. For the amplification of cDNA specific for the human COL1A2 gene, the following COL1A2_SF and COL1A2_SR oligonucleotides were used:
[0383] COL1A2_SF TGAACTTGTTGCTGAGGGCA,
[0384] COL1A2_SR CCAGTTCTTGGCTGGGATGT
[0385] The length of the amplified product was 195 bp.
[0386] The positive control included the amplicon from PCR on a matrix represented by a plasmid containing the COL1A2 and B2M gene cDNA sequences at a known concentration. The negative control included deionized water. The PCR products, i.e., the COL1A2 and B2M gene cDNA obtained by amplification, were quantified in real time using Bio-Rad CFX Manager 2.1 software (Bio-Rad, USA). The analysis results are shown in Figure 2. Figure 3 shown.
[0387] Figure 3 The results also demonstrate the feasibility of using the gene therapy DNA vector VTvaf17-COL1A2 to increase the expression level of the COL1A2 gene in eukaryotic cells.
[0388] Example 11.
[0389] Evidence of the ability of the gene therapy DNA vector VTvaf17-P4HA1 carrying the therapeutic gene, ie, P4HA1, to penetrate into eukaryotic cells and its functional activity at the level of therapeutic gene mRNA expression This example also demonstrates the feasibility of using a gene therapy DNA vector carrying a therapeutic gene.
[0390] Changes in the accumulation of P4HA1 therapeutic gene mRNA were evaluated in the Hs27 human foreskin fibroblast cell line (ATCC CRL-1634) 48 hours after transfection with the gene therapy DNA vector VTvaf17-P4HA1 carrying the human P4HA1 gene. The amount of mRNA was determined dynamically by the accumulation of cDNA amplicons in real-time PCR.
[0391] Hs27 human foreskin fibroblast cell line (Hs27) was cultured in Dulbecco's modified Eagle's medium (DMEM) under standard conditions (37°C, 5% CO2). 30-2020 TM ), the culture medium was supplemented with 10% bovine serum ( 30-2020 TM ). To achieve 90% confluence, cells were seeded into 24-well plates at 5 × 10 cells per well 24 hours before transfection. 4 The amount of cells was 100 cells / mL. Lipofectamine 3000 (ThermoFisher Scientific, USA) was used as a transfection reagent. According to the procedure described in Example 9, the gene therapy DNA vector VTvaf17-P4HA1 expressing the human P4HA1 gene was used for transfection. The B2M (β-2-microglobulin) gene listed in the GenBank database with the number NM 004048.2 was used as a reference gene. The Hs27 cell line transfected with the gene therapy DNA vector VTvaf17 lacking the therapeutic gene (the cDNA of the P4HA1 gene is not shown in the figure before and after transfection with the gene therapy DNA vector VTvaf17 lacking the inserted therapeutic gene) was used as a reference. RNA isolation, reverse transcription reaction, and real-time PCR were performed as described in Example 9, except that the oligonucleotides with different sequences from Example 9 were used. For the amplification of cDNA specific for the human P4HA1 gene, the following P4HA1_SF and P4HA1_SR oligonucleotides were used:
[0392] P4HA1_SF AAAAGTGCCTGGCTCTCTGG,
[0393] P4HA1_SR TGGCTCATCTTTCCGTGCAA
[0394] The length of the amplified product was 171 bp.
[0395] The positive control included the amplicon from PCR on a matrix represented by a plasmid containing the cDNA sequences of the P4HA1 and B2M genes at a known concentration. The negative control included deionized water. The real-time quantification of the PCR products, i.e., the cDNA of the P4HA1 and B2M genes obtained by amplification, was performed using Bio-Rad CFX Manager 2.1 software (Bio-Rad, USA). The analysis results are shown in Figure 2. Figure 4 shown.
[0396] Figure 4 The results also demonstrate the feasibility of using the gene therapy DNA vector VTvaf17-P4HA1 to increase the expression level of the P4HA1 gene in eukaryotic cells.
[0397] Example 12.
[0398] The ability of the gene therapy DNA vector VTvaf17-P4HA2 carrying the therapeutic gene, ie, the P4HA2 gene, to penetrate into eukaryotic cells and evidence of its functional activity at the level of therapeutic gene mRNA expression This example also demonstrates the feasibility of using a gene therapy DNA vector carrying a therapeutic gene.
[0399] Changes in the accumulation of P4HA2 therapeutic gene mRNA were evaluated in the Hs27 human foreskin fibroblast cell line (ATCC CRL-1634) 48 hours after transfection with the gene therapy DNA vector VTvaf17-P4HA2 carrying the human P4HA2 gene. The amount of mRNA was determined dynamically by the accumulation of cDNA amplicons in real-time PCR.
[0400] The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) under standard conditions (37°C, 5% CO2). 30-2020 TM ) 30-2020 TM ), the culture medium was supplemented with 10% bovine serum. To achieve 90% confluence, cells were seeded into 24-well plates 24 hours before transfection, with 5×10 4The amount of cells was 1000 cells / mL. Lipofectamine 3000 (ThermoFisher Scientific, USA) was used as a transfection reagent. According to the procedure described in Example 9, the gene therapy DNA vector VTvaf17-P4HA2 expressing the human P4HA2 gene was transfected. Hs27 cell culture transfected with the gene therapy DNA vector VTvaf17 lacking the therapeutic gene (the cDNA of the P4HA2 gene is not shown in the figure before and after transfection with the gene therapy DNA vector VTvaf17 lacking the inserted therapeutic gene) was used as a reference. RNA isolation, reverse transcription reaction, and real-time PCR were performed as described in Example 9, except that the oligonucleotides with different sequences from Example 9 were used. For the amplification of cDNA specific for the human P4HA2 gene, the following P4HA2_SF and P4HA2_SR oligonucleotides were used:
[0401] P4HA2_SF AGGTACCACCATGGCAACAG,
[0402] P4HA2_SR GTCTTGGGATCACGAACGGT
[0403] The length of the amplified product was 179 bp.
[0404] The positive control included the amplicon from PCR on a matrix represented by a plasmid containing the P4HA2 and B2M gene cDNA sequences at a known concentration. The B2M (beta-2-microglobulin) gene listed in the GenBank database under the number NM 004048.2 was used as a reference gene. The negative control included deionized water. The real-time quantification of the PCR products, i.e., the P4HA2 and B2M gene cDNA obtained by amplification, was performed using the Bio-Rad CFX Manager 2.1 software (Bio-Rad, USA). The analysis results are shown in Figure 2. Figure 5 shown.
[0405] Figure 5 The results also demonstrate the feasibility of using the gene therapy DNA vector VTvaf17-P4HA2 to increase the expression level of the P4HA2 gene in eukaryotic cells.
[0406] Example 13.
[0407] Evidence of the ability of the gene therapy DNA vector VTvaf17-COL7A1 carrying the therapeutic gene, COL7A1, to penetrate into eukaryotic cells and its functional activity at the level of therapeutic gene mRNA expression This example also demonstrates the feasibility of using a gene therapy DNA vector carrying a therapeutic gene.
[0408] 48 hours after transfection with the gene therapy DNA vector VTvaf17-COL7A1 carrying the human COL7A1 gene, HT297.T human dermal fibroblasts ( CRL-7782) cultures were evaluated for changes in the accumulation of the COL7A1 therapeutic gene mRNA. The amount of mRNA was determined dynamically by the accumulation of cDNA amplicons in real-time PCR.
[0409] The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) under standard conditions (37°C, 5% CO2). 30-2020 TM HT 297.T human dermal fibroblasts were cultured in a medium supplemented with 10% bovine serum ( 30-2020 TM ). To achieve 90% confluence, cells were seeded into 24-well plates 24 hours before transfection at 5x10 4 The amount of cells was 100 cells / mL. Lipofectamine 3000 (ThermoFisher Scientific, USA) was used as a transfection reagent. According to the procedure described in Example 9, the gene therapy DNA vector VTvaf17-COL7A1 expressing the human COL7A1 gene was used for transfection. The B2M (β-2-microglobulin) gene listed in the GenBank database with the number NM 004048.2 was used as a reference gene. Hs27 cell cultures transfected with the gene therapy DNA vector VTvaf17 lacking a therapeutic gene (the cDNA of the COL7A1 gene is not shown in the figure before and after transfection with the gene therapy DNA vector VTvaf17 lacking an inserted therapeutic gene) were used as a reference. RNA isolation, reverse transcription reaction, and real-time PCR were performed as described in Example 9, except that oligonucleotides with different sequences from Example 9 were used. For the amplification of cDNA specific for the human COL7A1 gene, the following COL7A1_SF and COL7A1_SR oligonucleotides were used:
[0410] COL7A1_SF CAAAGGAGAGATGGGGGAGC,
[0411] COL7A1_SR ATCATTTCCACTGGGGCCTG
[0412] The length of the amplified product was 184 bp.
[0413] The positive control included the amplicons from PCR on a matrix represented by a plasmid containing the COL7A1 and B2M gene cDNA sequences at known concentrations. The negative control included deionized water. The PCR products, i.e., the COL7A1 and B2M gene cDNA obtained by amplification, were quantified in real time using Bio-Rad CFX Manager 2.1 software (Bio-Rad, USA). The analysis results are shown in Figure 2. Figure 6 shown.
[0414] Figure 6 The results show that the level of specific mRNA of the human COL7A1 gene was greatly increased due to transfection of HT 297.T human dermal fibroblast cultures with the gene therapy DNA vector VTvaf17-COL7A1, confirming the ability of this vector to penetrate into eukaryotic cells and express the COL7A1 gene at the mRNA level. The results presented also confirm the feasibility of using the gene therapy DNA vector VTvaf17-COL7A1 in order to increase the expression level of the COL7A1 gene in eukaryotic cells.
[0415] Example 14.
[0416] The ability of the gene therapy DNA vector VTvaf17-CLCA2 carrying the therapeutic gene, ie, the CLCA2 gene, to penetrate into eukaryotic cells and evidence of its functional activity at the level of therapeutic gene mRNA expression This example also demonstrates the feasibility of using a gene therapy DNA vector carrying a therapeutic gene.
[0417] 48 hours after transfection with the gene therapy DNA vector VTvaf17-CLCA2 carrying the human CLCA2 gene, HT297.T human dermal fibroblasts ( CRL-7782) cultures were evaluated for changes in the accumulation of mRNA of the CLCA2 therapeutic gene. The amount of mRNA was determined dynamically by the accumulation of cDNA amplicons in real-time PCR.
[0418] The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) under standard conditions (37°C, 5% CO2). 30-2002 TM HT 297.T human dermal fibroblasts were cultured in a medium supplemented with 10% bovine serum ( 30-2020 TM ). To achieve 90% confluence, cells were seeded into 24-well plates 24 hours before transfection at 5x10 4The amount of cells was 100 cells / mL. Lipofectamine 3000 (ThermoFisher Scientific, USA) was used as a transfection reagent. According to the procedure described in Example 9, the gene therapy DNA vector VTvaf17-CLCA2 expressing the human CLCA2 gene was used for transfection. The B2M (β-2-microglobulin) gene listed in the GenBank database with the number NM 004048.2 was used as a reference gene. The HT 297.T cell line transfected with the gene therapy DNA vector VTvaf17 lacking a therapeutic gene (the cDNA of the CLCA2 gene is not shown in the figure before and after transfection with the gene therapy DNA vector VTvaf17 lacking an inserted therapeutic gene) was used as a reference. RNA isolation, reverse transcription reaction, and real-time PCR were performed as described in Example 9, except that the oligonucleotides had different sequences from Example 9. For the amplification of cDNA specific for the human CLCA2 gene, the following CLCA2_SF and CLCA2_SR oligonucleotides were used:
[0419] CLCA2_SF GGAGGCTCCTTTTCAGTGCT,
[0420] CLCA2_SR GTAGCCTGGCCCTGATCAAA
[0421] The length of the amplified product was 155 bp.
[0422] The positive control included the amplicon from PCR on a matrix represented by a plasmid containing the cDNA sequences of the CLCA2 and B2M genes at a known concentration. The negative control included deionized water. The real-time quantification of the PCR products, i.e., the cDNAs of the CLCA2 and B2M genes obtained by amplification, was performed using Bio-Rad CFX Manager 2.1 software (Bio-Rad, USA). The analysis results are shown in Figure 7 shown.
[0423] Figure 7 The results also demonstrate the feasibility of using the gene therapy DNA vector VTvaf17-CLCA2 to increase the expression level of the CLCA2 gene in eukaryotic cells.
[0424] Example 15.
[0425] The ability of the gene therapy DNA vector VTvaf17-ELN carrying the therapeutic gene, ie, the ELN gene, to penetrate into eukaryotic cells and evidence of its functional activity at the level of therapeutic gene mRNA expression. This example also demonstrates the feasibility of using a gene therapy DNA vector carrying a therapeutic gene.
[0426] Changes in the accumulation of mRNA of the ELN therapeutic gene were evaluated in HEKa human epidermal keratinocytes (ATCC PCS-200-011) cultures 48 hours after transfection with the gene therapy DNA vector VTvaf17-ELN carrying the human ELN gene. The amount of mRNA was determined dynamically by the accumulation of cDNA amplicons in real-time PCR.
[0427] The cells were grown in a keratinocyte growth kit ( PCS-200-040 TM HEKa human epidermal keratinocyte cultures were cultured in 24-well plates at 5 × 10 cells per well to achieve 90% confluence. 4 The amount of cells was 100 cells / mL. The transfection reagent was Lipofectamine 3000 (ThermoFisherScientific, USA). According to the procedure described in Example 9, the gene therapy DNA vector VTvaf17-ELN expressing the human ELN gene was transfected. HEKa cell cultures transfected with the gene therapy DNA vector VTvaf17 lacking the therapeutic gene (the cDNA of the ELN gene is not shown in the figure before and after transfection with the gene therapy DNA vector VTvaf17 lacking the inserted therapeutic gene) were used as a reference. RNA isolation, reverse transcription reaction, and real-time PCR were performed as described in Example 9, except that the oligonucleotides had different sequences from Example 9. For the amplification of cDNA specific for the human ELN gene, the following ELN_SF and ELN_SR oligonucleotides were used:
[0428] ELN_SF CCAGTTTGGCCTAGTGGGAG,
[0429] ELN_SR ATGGGAGACAATCCGAAGCC
[0430] The length of the amplified product was 159 bp.
[0431] The positive control included the amplicon from PCR on a matrix represented by a plasmid containing the ELN and B2M gene cDNA sequences at known concentrations. The B2M (beta-2-microglobulin) gene listed in the GenBank database under the number NM 004048.2 was used as a reference gene. The negative control included deionized water. The PCR products, i.e., the ELN and B2M gene cDNAs obtained by amplification, were quantified in real time using the Bio-Rad CFX Manager 2.1 software (Bio-Rad, USA). The analysis results are shown in Figure 2. Figure 8 shown.
[0432] Figure 8 The results also demonstrate the feasibility of using the gene therapy DNA vector VTvaf17-ELN to increase the expression level of the ELN gene in eukaryotic cells.
[0433] Example 16.
[0434] Evidence of the ability of the gene therapy DNA vector VTvaf17-PLOD1 carrying the therapeutic gene, ie, PLOD1 gene, to penetrate into eukaryotic cells and its functional activity demonstrated at the level of therapeutic gene mRNA expression. This example also demonstrates the feasibility of using a gene therapy DNA vector carrying a therapeutic gene.
[0435] After 48 hours of transfection with the gene therapy DNA vector VTvaf17-PLOD1 carrying the human PLOD1 gene, HEMa epidermal melanocyte cultures ( PCS-200-013), the changes in the accumulation of PLOD1 therapeutic gene mRNA were evaluated. The amount of mRNA was determined by the accumulation dynamics of cDNA amplicons in real-time PCR.
[0436] Under standard conditions (37°C, 5% CO2), dermal cell basal medium ( PCS-200-030 TM ) to culture HEMa primary human epidermal melanocyte culture, the culture medium is supplemented with adult melanocyte growth kit ( PCS-200-042 TM ). To achieve 90% confluence, cells were seeded into 24-well plates at 5 × 10 cells per well 24 hours before transfection. 4The amount of cells was 100 μg / mL. Lipofectamine 3000 (ThermoFisher Scientific, USA) was used as a transfection reagent. According to the procedure described in Example 9, the gene therapy DNA vector VTvaf17-PLOD1 expressing the human PLOD1 gene was used for transfection. HEMa cell cultures transfected with the gene therapy DNA vector VTvaf17 lacking a therapeutic gene (the cDNA of the PLOD1 gene is not shown in the figure before and after transfection with the gene therapy DNA vector VTvaf17 lacking an inserted therapeutic gene) were used as a reference. RNA isolation, reverse transcription reaction, and real-time PCR were performed as described in Example 9, except that the oligonucleotides had different sequences from those in Example 9. For the amplification of cDNA specific for the human PLOD1 gene, the following PLOD1_SF and PLOD1_SR oligonucleotides were used:
[0437] PLOD1_SFGCCTCCACCTTCACCATCAA,
[0438] PLOD1_SR AAGGAGACTGCGATGTAGCG
[0439] The length of the amplified product was 197 bp.
[0440] The positive control included the amplicon from PCR on a matrix represented by a plasmid containing cDNA sequences of the PLOD1 and B2M genes at known concentrations. The B2M (beta-2-microglobulin) gene listed in the GenBank database with the number NM 004048.2 was used as a reference gene. The negative control included deionized water. The PCR products, i.e., the PLOD1 and B2M gene cDNA obtained by amplification, were quantified in real time using Bio-Rad CFXManager 2.1 software (Bio-Rad, USA). The analysis results are shown in Figure 2. Fig. 9 shown.
[0441] Fig. 9 The results also demonstrate the feasibility of using the gene therapy DNA vector VTvaf17-PLOD1 to increase the expression level of the PLOD1 gene in eukaryotic cells.
[0442] Example 17.
[0443] The gene therapy DNA vector VTvaf17-COL1A1 carrying the COL1A1 gene was used to improve the efficacy and feasibility of COL1A1 protein expression in mammalian cells.
[0444] After HDFa human dermal fibroblasts (ATCC PCS-201-01) were transfected with the DNA vector VTvaf17-COL1A1 carrying the human COL1A1 gene, changes in COL1A1 protein concentration in lysates of these cells were evaluated.
[0445] HDFa human dermal fibroblast cultures were grown as described in Example 9.
[0446] To achieve 90% confluence, cells were seeded into 24-well plates at 5x10 cells per well 24 hours before transfection. 4 The amount of cells was 100 μg. The transfection was performed using the 6th generation SuperFect transfection reagent (Qiagen, Germany). An aqueous dendrimer solution without DNA vector (A) and a DNA vector VTvaf17 lacking the cDNA of the COL1A1 gene were used as references, and a DNA vector VTvaf17-COL1A1 carrying the human COL1A1 gene (C) was used as a transfection agent. DNA-dendrimers were prepared according to the manufacturer's procedure (QIAGEN, SuperFect Transfection Reagent Handbook, 2002) with some modifications. For cell transfection in 1 well of a 24-well plate, culture medium was added to 1 μg of DNA vector dissolved in TE buffer to a final volume of 60 μL, then 5 μL of SuperFect transfection reagent was added and gently mixed by pipetting 5 times. The complex was incubated at room temperature for 10-15 minutes. The culture medium was then removed from the well and the well was rinsed with 1 ml of PBS buffer. 350 μL of medium containing 10 μg / ml gentamicin was added to the resulting complex, mixed gently, and then added to the cells. The cells and complex were incubated at 37°C and 5% CO2 for 2-3 h.
[0447] Then the culture medium was carefully removed and the living cell matrix was rinsed with 1 ml of PBS buffer. Then, a culture medium containing 10 μg / ml of gentamicin was added and incubated at 37° C. in the presence of 5% CO 2 for 24-48 h.
[0448] After transfection, the cells were washed 3 times with PBS, and then 1 ml of PBS was added to the cells and freeze / thawed 3 times. The suspension was then centrifuged at 15000 rpm for 15 minutes, and the supernatant was collected for quantification and determination of the therapeutic protein.
[0449] COL1A1 protein was measured by enzyme-linked immunosorbent assay (ELISA) using human COL1A1 / Collagen I Alpha 1 ELISA kit (Sandwich ELISA) (LifeSpan BioSciences, LS-F22003-1) according to the manufacturer's method, and optical density detection was performed using ChemWell Automatic EIA and Chemistry Analyser (Awareness Technology Inc., USA).
[0450] To measure the concentration values, a calibration curve was used, which was constructed using reference samples from the kit with known concentrations of COL1A1 protein. The sensitivity was 188 pg / ml and the measurement range was 313 pg / ml-20000 pg / ml. The results were statistically processed and visualized using R-3.0.2 (https: / / www.r-project.org / ). The analysis results are shown in Fig.10 shown.
[0451] Fig.10 The results also demonstrate the feasibility of using the gene therapy DNA vector VTvaf17-COL1A1 to increase the expression level of the COL1A1 gene in eukaryotic cells.
[0452] Example 18.
[0453] Evidence for the efficacy and feasibility of using the gene therapy DNA vector VTvaf17-COL1A2 carrying the COL1A2 gene to increase COL1A2 protein expression in mammalian cells.
[0454] Changes in COL1A2 protein concentration in HDFa human dermal fibroblasts (ATCC PCS-201-01) were evaluated after transfection of these cell lysates with the DNA vector VTvaf17-COL1A2 carrying the human COL1A2 gene. The cells were grown as described in Example 10.
[0455] The sixth generation SuperFect transfection reagent (Qiagen, Germany) was used for transfection. An aqueous dendrimer solution without a DNA carrier (A) and a DNA vector VTvaf17 lacking the COL1A2 gene cDNA (B) were used as references, and a DNA vector VTvaf17-COL1A2 carrying the human COL1A2 gene (C) was used as a transfection agent. Preparation of DNA dendrimers and transfection of HDFa cells were performed according to the procedure described in Example 17.
[0456] After transfection, 0.1 ml 1N HCl was added to 0.5 ml culture broth, mixed thoroughly, and incubated at room temperature for 10 min. Then, 0.1 ml 1.2 M NaOH / 0.5 M HEPES (pH 7-7.6) was added to neutralize the mixture and stirred thoroughly. The supernatant was collected and used for the determination of therapeutic proteins. According to the manufacturer's method, human COL1A2 / Collagen Iα2 ELISA kit (Sandwich ELISA) (LifeSpan Biosciences, LS-F26740) was used to determine COL1A2 protein by enzyme-linked immunosorbent assay (ELISA), wherein ChemWell Automatic EIA and Chemistry Analyser (Awareness Technology Inc., USA) were used for optical density detection.
[0457] To measure the concentration values, a calibration curve was used, which was constructed using reference samples from the kit with known concentrations of COL1A2 protein. The sensitivity was at least 100 pg / ml, and the measurement range was 500 pg / ml-10000 pg / ml. R-3.0.2 was used for statistical processing and data visualization of the results (https: / / www.r-project.org / ). The analysis results are shown in Fig.11 shown.
[0458] Fig.11 It is shown that transfection of HDFa primary human dermal fibroblast cultures with the gene therapy DNA vector VTvaf17-COL1A2 resulted in an increase in COL1A2 protein concentration compared to reference samples, confirming the ability of the vector to penetrate into eukaryotic cells and express the COL1A2 gene at the protein level. The presented results also confirm the feasibility of using the gene therapy DNA vector VTvaf17-COL1A2 in order to increase the expression level of COL1A2 in eukaryotic cells.
[0459] Example 19.
[0460] Evidence for the efficacy and feasibility of using the gene therapy DNA vector VTvaf17-P4HA1 carrying the P4HA1 gene to enhance P4HA1 protein expression in mammalian cells.
[0461] Changes in P4HA1 protein concentration in lysates of Hs27 human foreskin fibroblast cell line (ATCC-CRL-1634) were evaluated after transfection of these cells with the gene therapy DNA vector VTvaf17-P4HA1 carrying the human P4HA1 gene. Cells were cultured as described in Example 11.
[0462] The 6th generation SuperFect transfection reagent (Qiagen, Germany) was used for transfection. An aqueous dendrimer solution without a DNA carrier (A) and a DNA vector VTvaf17 lacking the P4HA1 gene cDNA (B) were used as references, and a DNA vector VTvaf17-P4HA1 carrying the human P4HA1 gene (C) was used as a transfection agent. Preparation of DNA dendrimers and transfection of Hs27 cells were performed according to the procedures described in Example 17.
[0463] After transfection, 0.1 ml of 1N HCl was added to 0.5 ml of culture broth, mixed thoroughly, and incubated at room temperature for 10 minutes. Then, the mixture was neutralized by adding 0.1 ml of 1.2 M NaOH / 0.5 M HEPES (pH 7-7.6) and stirred thoroughly. The supernatant was collected and used for the determination of therapeutic proteins. P4HA1 protein was determined by enzyme-linked immunosorbent assay (ELISA) using human P4HA1 ELISA kit (Sandwich ELISA) (LifeSpan BioSciences, LS-F12242-1) according to the manufacturer's method, wherein optical density detection was performed using ChemWell Automated EIA and Chemistry Analyser (Awareness Technology Inc., USA).
[0464] To measure the concentration values, a calibration curve was used, which was constructed using reference samples from the kit with known concentrations of P4HA1 protein. The sensitivity was at least 625 pg / ml, and the measurement range was 625 pg / ml-40000 pg / ml. R-3.0.2 was used for statistical processing and data visualization of the results (https: / / www.r-project.org / ). The analysis results are shown in Fig.12 shown.
[0465] Fig.12It was shown that transfection of the Hs27 human foreskin fibroblast cell line with the gene therapy DNA vector VTvaf17-P4HA1 resulted in an increase in the P4HA1 protein concentration compared to a reference sample, which confirmed the ability of the vector to penetrate into eukaryotic cells and express the P4HA1 gene at the protein level. The presented results also confirmed the feasibility of using the gene therapy DNA vector VTvaf17-P4HA1 in order to increase the expression level of the P4HA1 gene in eukaryotic cells.
[0466] Example 20.
[0467] Evidence for the efficacy and feasibility of using the gene therapy DNA vector VTvaf17-P4HA2 carrying the P4HA2 gene to enhance P4HA2 protein expression in mammalian cells.
[0468] Changes in P4HA2 protein concentration in lysates of Hs27 human foreskin fibroblast cell line (ATCC-CRL-1634) were evaluated after transfection of these cells with the gene therapy DNA vector VTvaf17-P4HA2 carrying the human P4HA2 gene. Cells were cultured as described in Example 12.
[0469] The 6th generation SuperFect transfection reagent (Qiagen, Germany) was used for transfection. An aqueous dendrimer solution without a DNA carrier (A) and a DNA vector VTvaf17 lacking the P4HA2 gene cDNA (B) were used as references, and a DNA vector VTvaf17-P4HA2 carrying the human P4HA2 gene (C) was used as a transfection agent. Preparation of DNA dendrimers and transfection of Hs27 cells were performed according to the procedures described in Example 17.
[0470] After transfection, 0.1 ml of 1N HCl was added to 0.5 ml of culture broth, mixed thoroughly, and incubated at room temperature for 10 minutes. Then, the mixture was neutralized by adding 0.1 ml of 1.2 M NaOH / 0.5 M HEPES (pH 7-7.6) and stirred thoroughly. The supernatant was collected and used for the determination of therapeutic proteins.
[0471] P4HA2 protein was measured by enzyme-linked immunosorbent assay (ELISA) using a human P4HA2 ELISA kit (Sandwich ELISA) (LifeSpan BioSciences, LS-F33689-1), with optical density detection using a ChemWell Automated EIA and Chemistry Analyser (Awareness Technology Inc., USA).
[0472] To measure the concentration values, a calibration curve was used, which was constructed using reference samples from the kit with known concentrations of P4HA2 protein. The sensitivity was at least 469 pg / ml, and the measurement range was 780 pg / ml-50000 pg / ml. R-3.0.2 was used for statistical processing and data visualization of the results (https: / / www.r-project.org / ). The analysis results are shown in Fig.13 shown.
[0473] Fig.13 It was shown that transfection of the Hs27 human foreskin fibroblast cell line with the gene therapy DNA vector VTvaf17-P4HA2 resulted in an increase in the P4HA2 protein concentration compared to a reference sample, which confirmed the ability of the vector to penetrate into eukaryotic cells and express the P4HA2 gene at the protein level. The presented results also confirmed the feasibility of using the gene therapy DNA vector VTvaf17-P4HA2 in order to increase the expression level of the P4HA2 gene in eukaryotic cells.
[0474] Example 21.
[0475] Evidence for the efficacy and feasibility of using the gene therapy DNA vector VTvaf17-COL7A1 carrying the COL7A1 gene to increase COL7A1 protein expression in mammalian cells.
[0476] The DNA vector VTvaf17-COL7A1 carrying the human COL7A1 gene was used to transfect HT 297.T human fibroblasts ( CRL-7782 TM ) and the changes in COL7A1 protein concentration in the lysates of these cells were evaluated. The cells were cultured as described in Example 13.
[0477] The 6th generation SuperFect transfection reagent (Qiagen, Germany) was used for transfection. An aqueous dendrimer solution without a DNA carrier (A) and a DNA vector VTvaf17 lacking the COL7A1 gene cDNA (B) were used as references, and a DNA vector VTvaf17-COL7A1 carrying the human COL7A1 gene (C) was used as a transfection agent. Preparation of DNA dendrimers and transfection of HT 297.T cells were performed according to the procedures described in Example 17.
[0478] After transfection, 0.1 ml 1N HCl was added to 0.5 ml culture broth, mixed thoroughly, and incubated at room temperature for 10 minutes. Then, the mixture was neutralized by adding 0.1 ml 1.2 M NaOH / 0.5 M HEPES (pH 7-7.6) and stirred thoroughly. The supernatant was collected and used for the determination of therapeutic proteins. According to the manufacturer's method, human COL7A1 / Collagen VII ELISA kit (Sandwich ELISA) (LifeSpan BioSciences, LS-F11164-1) was used to measure COL7A1 protein by enzyme-linked immunosorbent assay (ELISA), wherein ChemWell Automated EIA and Chemistry Analyser (Awareness Technology Inc., USA) were used for optical density detection.
[0479] To measure the concentration values, a calibration curve was used, which was constructed using reference samples from the kit with known concentrations of COL7A1 protein. The sensitivity was at least 156 pg / ml, and the measurement range was 156 pg / ml-10000 pg / ml. R-3.0.2 was used for statistical processing and data visualization of the results (https: / / www.r-project.org / ). The analysis results are shown in Fig.14 shown.
[0480] Fig.14 It is shown that transfection of HT 297.T human fibroblasts with the gene therapy DNA vector VTvaf17-COL7A1 resulted in an increase in the COL7A1 protein concentration compared to a reference sample, which confirms the ability of the vector to penetrate into eukaryotic cells and express the COL7A1 gene at the protein level. The presented results also confirm the feasibility of using the gene therapy DNA vector VTvaf17-COL7A1 in order to increase the expression level of the COL7A1 gene in eukaryotic cells.
[0481] Example 22.
[0482] Evidence for the efficacy and feasibility of using the gene therapy DNA vector VTvaf17-CLCA2 carrying the CLCA2 gene to increase CLCA2 protein expression in mammalian cells.
[0483] HT 297.T human fibroblasts ( CRL-7782 TM ) and the changes in CLCA2 protein concentration in the lysates of these cells were evaluated. The cells were cultured as described in Example 14.
[0484] The 6th generation SuperFect transfection reagent (Qiagen, Germany) was used for transfection. An aqueous dendrimer solution without a DNA carrier (A) and a DNA vector VTvaf17 lacking the cDNA of the CLCA2 gene (B) were used as references, and a DNA vector VTvaf17-CLCA2 carrying the human CLCA2 gene (C) was used as a transfection agent. Preparation of DNA dendrimers and transfection of HT 297.T cells were performed according to the procedures described in Example 17.
[0485] After transfection, 0.1 ml 1N HCl was added to 0.5 ml culture broth, mixed thoroughly, and incubated at room temperature for 10 minutes. Then, the mixture was neutralized by adding 0.1 ml 1.2 M NaOH / 0.5 M HEPES (pH 7-7.6) and stirred thoroughly. The supernatant was collected and used for the determination of therapeutic proteins. According to the manufacturer's method, human calcium-activated chloride channel regulator 2 (CLCA2) ELISA kit (MyBioSource, MBS7242681) was used to measure CLCA2 protein by enzyme-linked immunosorbent assay (ELISA), wherein ChemWell Automated EIA and Chemistry Analyser (Awareness Technology Inc., USA) were used for optical density detection.
[0486] To measure the concentration values, a calibration curve was used, which was constructed using reference samples from the kit with known concentrations of CLCA2 protein. The sensitivity was at least 1 pg / ml, and the measurement range was 50 pg / ml-1000 pg / ml. R-3.0.2 was used for statistical processing and data visualization of the results (https: / / www.r-project.org / ). The analysis results are shown in Fig.15 shown.
[0487] Fig.15 It is shown that transfection of HT 297.T human fibroblasts with the gene therapy DNA vector VTvaf17-CLCA2 leads to an increase in CLCA2 protein concentration compared to a reference sample, which confirms the ability of the vector to penetrate into eukaryotic cells and express the CLCA2 gene at the protein level. The presented results also confirm the feasibility of using the gene therapy DNA vector VTvaf17-CLCA2 in order to increase the expression level of the CLCA2 gene in eukaryotic cells.
[0488] Example 23.
[0489] Evidence for the efficacy and feasibility of using the gene therapy DNA vector VTvaf17-ELN carrying the ELN gene to enhance ELN protein expression in mammalian cells.
[0490] Changes in ELN protein concentration in lysates of HEKa epidermal keratinocyte cultures (ATCC PCS-200-011) were evaluated after transfection of these cells with the DNA vector VTvaf17-ELN carrying the human ELN gene. The cells were cultured as described in Example 15.
[0491] The sixth generation SuperFect transfection reagent (Qiagen, Germany) was used for transfection. An aqueous dendrimer solution without a DNA carrier (A) and a DNA vector VTvaf17 lacking the ELN gene cDNA (B) were used as references, and a DNA vector VTvaf17-ELN carrying the human ELN gene (C) was used as a transfection agent. Preparation of DNA dendrimers and transfection of HEKa cells were performed according to the procedures described in Example 17.
[0492] After transfection, 0.1 ml of 1N HCl was added to 0.5 ml of culture broth, mixed thoroughly, and incubated at room temperature for 10 minutes. Then, the mixture was neutralized by adding 0.1 ml of 1.2 M NaOH / 0.5 M HEPES (pH 7-7.6) and stirred thoroughly. The supernatant was collected and used for the determination of therapeutic proteins.
[0493] ELN protein was measured by enzyme-linked immunosorbent assay (ELISA) using an elastin ELISA kit (Reddot Biotech, RD-ELN-Ra) according to the manufacturer's method, with optical density detection using ChemWell Automated EIA and Chemistry Analyser (Awareness Technology Inc., USA).
[0494] To measure the concentration values, a calibration curve was used, which was constructed using reference samples from the kit with known concentrations of ELN protein. The sensitivity was at least 12.7 pg / ml, and the measurement range was 31.25 pg / ml-2000 pg / ml. R-3.0.2 was used for statistical processing and data visualization of the results (https: / / www.r-project.org / ). The analysis results are shown in Fig.16 shown.
[0495] Fig.16It is shown that transfection of HEKa epidermal keratinocyte cultures with the gene therapy DNA vector VTvaf17-ELN resulted in an increase in ELN protein concentration compared to a reference sample, which confirms the ability of the vector to penetrate into eukaryotic cells and express the ELN gene at the protein level. The presented results also confirm the feasibility of utilizing the gene therapy DNA vector VTvaf17-ELN in order to increase the expression level of the ELN gene in eukaryotic cells.
[0496] Example 24.
[0497] Evidence for the efficacy and feasibility of using the gene therapy DNA vector VTvaf17-PLOD1 carrying the PLOD1 gene to increase PLOD1 protein expression in mammalian cells.
[0498] HEMa epidermal melanocyte cultures were transfected with the DNA vector VTvaf17-PLOD1 carrying the human PLOD1 gene ( PCS-200-013), the changes in PLOD1 protein concentration in the lysates of these cells were evaluated. The cells were cultured as described in Example 16.
[0499] The sixth generation SuperFect transfection reagent (Qiagen, Germany) was used for transfection. An aqueous dendrimer solution without a DNA carrier (A) and a DNA vector VTvaf17 lacking the PLOD1 gene cDNA (B) were used as references, and a DNA vector VTvaf17-PLOD1 carrying the human PLOD1 gene (C) was used as a transfection agent. Preparation of DNA dendrimers and transfection of HEMa cells were performed according to the procedures described in Example 17.
[0500] After transfection, 0.1 ml of 1N HCl was added to 0.5 ml of culture broth, mixed thoroughly, and incubated at room temperature for 10 minutes. Then, the mixture was neutralized by adding 0.1 ml of 1.2 M NaOH / 0.5 M HEPES (pH 7-7.6) and stirred thoroughly. The supernatant was collected and used for the determination of therapeutic proteins.
[0501] PLOD1 protein was measured by enzyme-linked immunosorbent assay (ELISA) using Human PLOD / PLOD1 ELISA Kit (Sandwich ELISA) (LifeSpan BioSciences, LS-F9705-1) according to the manufacturer's method, with optical density detection using ChemWell Automated EIA and Chemistry Analyser (Awareness Technology Inc., USA).
[0502] To measure the concentration values, a calibration curve was used, which was constructed using reference samples from the kit with known concentrations of PLOD1 protein. The sensitivity was at least 66 pg / ml, and the measurement range was 156 pg / ml-10000 pg / ml. R-3.0.2 was used for statistical processing and data visualization of the results (https: / / www.r-project.org / ). The analysis results are shown in Fig.17 shown.
[0503] Fig.17 The results also demonstrate the feasibility of using the gene therapy DNA vector VTvaf17-PLOD1 to increase the expression level of the PLOD1 gene in eukaryotic cells.
[0504] Example 25.
[0505] Evidence for the efficacy and feasibility of using the gene therapy DNA vector VTvaf17-P4HA2 carrying the P4HA2 gene to enhance P4HA2 protein expression in mammalian cells.
[0506] To confirm the efficacy of the gene therapy DNA vector VTvaf17-P4HA2 carrying the therapeutic gene, namely the P4HA2 gene, and the feasibility of its use, the changes in the P4HA2 protein concentration in human skin were evaluated after injection of the gene therapy DNA vector VTvaf17-P4HA2 carrying the human P4HA2 gene.
[0507] To analyze the changes in P4HA2 protein concentration, the gene therapy DNA vector VTvaf17-P4HA2 carrying the P4HA2 gene was injected into the forearm skin of three patients, while the placebo injected at the same time was the gene therapy DNA vector VTvaf17 lacking the cDNA of the P4HA2 gene.
[0508] Patient 1, female, 44 years old (P1); Patient 2, female, 61 years old (P2); Patient 3, male, 50 years old (P3). Polyethylenimine transfection reagent cGMP grade in vivo jetPEI (Polyplus Transfection, France) was used as a transport system. Gene therapy DNA vector VTvaf17-P4HA2 containing P4HA2 gene cDNA and gene therapy DNA vector VTvaf17 without P4HA2 gene cDNA used as placebo were dissolved in sterile nuclease-free water. To obtain gene constructs, DNA-cGMP grade in vivo-JetPEI complexes were prepared according to the manufacturer's recommendations.
[0509] For each genetic construct, the gene therapy DNA vector VTvaf17 (placebo) and the gene therapy DNA vector VTvaf17-P4HA2 carrying the P4HA2 gene were injected in an amount of 1 mg using a channel method (with a 30G needle to a depth of 3 mm). For each genetic construct, the injectable volume of the gene therapy DNA vector VTvaf17 (placebo) and the gene therapy DNA vector VTvaf17-P4HA2 carrying the P4HA2 gene was 0.3 ml. The injection point of each genetic construct was located at 8 to 10 cm intervals in the forearm.
[0510] Biopsy samples were taken on the second day after injection of the genetic construct of the gene therapy DNA vector. Using the skin biopsy device Epitheasy 3.5 (Medax SRL, Italy), biopsy samples were taken from the patient's skin at the site where the gene therapy DNA vector VTvaf17-P4HA2 carrying the P4HA2 gene was injected (I); the gene therapy DNA vector VTvaf17 (placebo) (II) and from the intact skin (III). The patient's skin in the biopsy site was initially rinsed with sterile saline and anesthetized with lidocaine solution. The biopsy sample size was approximately 10 mm3 and the weight was approximately 11 mg. The sample was placed in a buffer solution containing 50 mM Tris-HCl (pH 7.6), 100 mM NaCl, 1 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride, and homogenized to obtain a homogenized suspension. The suspension was then centrifuged at 14,000 g for 10 minutes. The supernatant was collected and used to measure the therapeutic protein by enzyme-linked immunosorbent assay (ELISA) using a human P4HA2 ELISA kit (Sandwich ELISA) (LifeSpan BioSciences, LS-F33689-1) according to the manufacturer's protocol, with optical density detection using ChemWell Automated EIA and Chemistry Analyser (Awareness Technology Inc., USA).
[0511] To measure the concentration values, a calibration curve was used, which was constructed using reference samples from the kit with known concentrations of P4HA2 protein. The sensitivity was at least 469 pg / ml, and the measurement range was 780 pg / ml-50000 pg / ml. R-3.0.2 was used for statistical processing and data visualization of the results (https: / / www.r-project.org / ). The analysis results are shown in Fig.18 shown.
[0512] Fig.18 The results showed that the P4HA2 protein concentration in the skin of all three patients was increased at the injection site of the gene therapy DNA vector VTvaf17-P4HA2 carrying the human P4HA2 therapeutic gene, compared with the P4HA2 protein concentration in the injection site of the gene therapy DNA vector VTvaf17 (placebo) lacking the human P4HA2 gene, indicating the efficacy of the gene therapy DNA vector VTvaf17-P4HA2 and confirming the feasibility of its use (especially after intradermal injection of the gene therapy DNA vector in human tissue).
[0513] Example 26.
[0514] Evidence for the efficacy and feasibility of using the gene therapy DNA vector VTvaf17-P4HA1 carrying the P4HA1 gene to enhance P4HA1 protein expression in mammalian cells.
[0515] To confirm the efficacy of the gene therapy DNA vector VTvaf17-P4HA1 carrying the P4HA1 therapeutic gene and the feasibility of its use, the changes in the P4HA1 protein concentration in human skin were evaluated after injection of the gene therapy DNA vector VTvaf17-P4HA1 carrying the therapeutic gene, i.e., the human P4HA1 gene.
[0516] To analyze the changes in P4HA1 protein concentration, the gene therapy DNA vector VTvaf17-P4HA1 carrying the P4HA1 gene was injected into the skin of three patients together with a transport molecule. The placebo injected at the same time was a gene therapy DNA vector VTvaf17 lacking the cDNA of the P4HA1 gene and a transport molecule.
[0517] Patient 1, male, 59 years old (P1); Patient 2, female, 56 years old (P2); Patient 3, male, 58 years old (P3). Polyethylenimine transfection reagent cGMP grade in vivo jetPEI (Polyplus Transfection, France) was used as the delivery system; sample preparation was performed according to the manufacturer's recommendations.
[0518] For each genetic construct, the gene therapy DNA vector VTvaf17 (placebo) and the gene therapy DNA vector VTvaf17-P4HA1 carrying the P4HA1 gene were injected in an amount of 1 mg using a channel method (with a 30G needle to a depth of about 1 mm). For each genetic construct, the injectable volume of the gene therapy DNA vector VTvaf17 (placebo) and the gene therapy DNA vector VTvaf17-P4HA1 carrying the P4HA1 gene was 0.3 ml. The injection point of each genetic construct was located 5 cm from each other.
[0519] After injection of the genetic construct of the gene therapy DNA vector, a biopsy sample was taken on the second day. Using a skin biopsy device, biopsy samples were taken from the patient's skin at the site where the gene therapy DNA vector VTvaf17-P4HA1 carrying the P4HA1 gene was injected (I); the gene therapy DNA vector VTvaf17 (placebo) (II) and from the intact skin (III). The patient's skin in the biopsy site was initially rinsed with sterile saline and anesthetized with lidocaine solution. The biopsy sample size was approximately 10 mm3 and the weight was approximately 11 mg. The sample was placed in a buffer solution containing 50 mM Tris-HCl (pH 7.6), 100 mM NaCl, 1 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride, and homogenized to obtain a homogenized suspension. The suspension was then centrifuged at 14,000 g for 10 minutes. The supernatant was collected and used for the determination of the therapeutic protein.
[0520] P4HA1 ELISA kit (Sandwich ELISA) (LifeSpan BioSciences, LS-F12242-1) was used for the determination of therapeutic proteins by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's method, wherein the optical density detection was performed using ChemWell Automated EIA and Chemistry Analyser (Awareness Technology Inc., USA). The sensitivity was 0.625 ng / ml and the measurement range was 0.625 ng / ml-40 ng / ml.
[0521] To measure the concentration values, a calibration curve was used, which was constructed using reference samples from the kit with known concentrations of P4HA1 protein. The sensitivity was at least 625 pg / ml, and the measurement range was 625 pg / ml-40000. R-3.0.2 was used for statistical processing and data visualization of the results (https: / / www.r-project.org / ). The analysis results are shown in Fig.19 shown.
[0522] Fig.19 The results showed that the P4HA1 protein concentration in the skin of all three patients was increased at the injection site of the gene therapy DNA vector VTvaf17-P4HA1 carrying the therapeutic gene (i.e., the human P4HA1 gene) compared to the P4HA1 protein concentration in the injection site of the gene therapy DNA vector VTvaf17 (placebo) lacking the human P4HA1 gene, indicating the efficacy of the gene therapy DNA vector VTvaf17-P4HA1 and confirming the feasibility of its use (especially after intradermal injection of the gene therapy DNA vector in human tissue).
[0523] Example 27.
[0524] Evidence of the efficacy and feasibility of using a gene therapy DNA vector VTvaf17-COL7A1 carrying the COL7A1 gene, a gene therapy DNA vector VTvaf17-CLCA2 carrying the CLCA2 gene, a gene therapy DNA vector VTvaf17-ELN carrying the ELN gene, and a gene therapy DNA vector VTvaf17-PLOD1 carrying the PLOD1 gene in combination to increase the expression levels of COL7A1, CLCA2, ELN, and PLOD1 proteins in human tissues.
[0525] To demonstrate the efficacy of gene therapy DNA vectors VTvaf17-COL7A1 carrying COL7A1 gene, VTvaf17-CLCA2 carrying CLCA2 gene, VTvaf17-ELN carrying ELN gene, and VTvaf17-PLOD1 carrying PLOD1 gene and the feasibility of their use, changes in the protein concentrations of COL7A1, CLCA2, ELN, and PLOD1 in human skin injected simultaneously with a mixture of gene therapy DNA vectors VTvaf17-COL7A1 carrying COL7A1 gene, gene therapy DNA vectors VTvaf17-CLCA2 carrying CLCA2 gene, gene therapy DNA vectors VTvaf17-ELN carrying ELN gene, and gene therapy DNA vectors VTvaf17-PLOD1 carrying PLOD1 gene were evaluated.
[0526] To analyze the changes in the protein concentrations of COL7A1, CLCA2, ELN and PLOD1, a mixture of gene therapy DNA vector VTvaf17-COL7A1 carrying the COL7A1 gene, gene therapy DNA vector VTvaf17-CLCA2 carrying the CLCA2 gene, gene therapy DNA vector VTvaf17-ELN carrying the ELN gene and gene therapy DNA vector VTvaf17-PLOD1 carrying the PLOD1 gene was injected into the forearm skin of three patients, and the placebo injected at the same time was the gene therapy DNA vector VTvaf17 lacking the cDNA of the COL7A1, CLCA2, ELN and PLOD1 genes.
[0527] Patient 1, female, 38 years old (P1); Patient 2, male, 48 years old (P2); Patient 3, male, 52 years old (P3). Polyethyleneimine transfection reagent cGMP grade in vivo jetPEI (Polyplus Transfection, France) was used as a transport system. A mixture of gene therapy DNA vectors VTvaf17-COL7A1 carrying the COL7A1 gene, gene therapy DNA vectors VTvaf17-CLCA2 carrying the CLCA2 gene, gene therapy DNA vectors VTvaf17-ELN carrying the ELN gene, and gene therapy DNA vectors VTvaf17-PLOD1 carrying the PLOD1 gene (at a ratio of 1:1:1:1) and a gene therapy DNA vector VTvaf17 used as a placebo (not containing cDNAs of COL7A1, CLCA2, ELN, and PLOD1 genes) were each dissolved in sterile nuclease-free water. To obtain gene constructs, DNA-cGMP grade in vivo jetPEI complexes were prepared according to the manufacturer's recommendations.
[0528] For each genetic construct, a mixture of gene therapy DNA vector VTvaf17 (placebo) and gene therapy DNA vector VTvaf17-COL7A1, gene therapy DNA vector VTvaf17-CLCA2, gene therapy DNA vector VTvaf17-ELN and gene therapy DNA vector VTvaf17-PLOD1 was injected in an amount of 4 mg using a channel method (with a 30G needle to a depth of 3 mm). For each genetic construct, the injectable volume of a mixture of gene therapy DNA vector VTvaf17 (placebo) and gene therapy DNA vector VTvaf17-COL7A1, gene therapy DNA vector VTvaf17-CLCA2, gene therapy DNA vector VTvaf17-ELN and gene therapy DNA vector VTvaf17-PLOD1 was 1.2 ml. The injection point of each genetic construct was located at 8 to 10 cm intervals at the forearm skin site.
[0529] Biopsy samples were taken on the second day after injection of the gene therapy DNA vector. Using the skin biopsy device Epitheasy 3.5 (Medax SRL, Italy), biopsy samples were taken from the patient's skin at the site where the gene therapy DNA vector VTvaf17-COL7A1 carrying the COL7A1 gene, the gene therapy DNA vector VTvaf17-CLCA2 carrying the CLCA2 gene, the gene therapy DNA vector VTvaf17-ELN carrying the ELN gene, and the mixture of the gene therapy DNA vector VTvaf17-PLOD1 carrying the PLOD1 gene (I), the gene therapy DNA vector VTvaf17 (placebo) (II), and from the intact skin (III). The patient's skin in the biopsy site was preliminarily rinsed with sterile saline and anesthetized with lidocaine solution. The biopsy sample size was approximately 10 mm3 and the weight was approximately 11 mg. The sample was placed in a buffer solution containing 50 mM Tris-HCl (pH 7.6), 100 mM NaCl, 1 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride, and homogenized to obtain a homogenized suspension. The suspension was then centrifuged at 14,000 g for 10 minutes. The supernatant was collected and used to measure the therapeutic protein, as described in Example 21 (quantification of COL7A1 protein), Example 22 (quantification of CLCA2 protein), Example 23 (quantification of ELN protein), and Example 24 (quantification of PLOD1 protein).
[0530] To measure the concentration values, calibration curves were used, which were constructed using reference samples from each kit with known concentrations of COL7A1, CLCA2, ELN and PLOD1 proteins. R-3.0.2 was used for statistical processing of the results and data visualization (https: / / www.r-project.org / ). Figures derived from the assays are shown in Fig. 20 middle.
[0531] Fig. 20The results show that the concentrations of COL7A1, CLCA2, ELN and PLOD1 proteins in the injection site of the gene therapy DNA vector VTvaf17-COL7A1 carrying the COL7A1 gene, the gene therapy DNA vector VTvaf17-CLCA2 carrying the CLCA2 gene, the gene therapy DNA vector VTvaf17-ELN carrying the ELN gene, and the gene therapy DNA vector VTvaf17-PLN carrying the human PLOD1 gene were significantly higher than those in the injection site of the gene therapy DNA vector VTvaf17 (placebo) lacking the human COL7A1, CLCA2, ELN and PLOD1 genes. The increase in COL7A1, CLCA2, ELN and PLOD1 protein concentrations in the skin of all three patients at the injection site of the mixture of gene therapy DNA vectors VTvaf17-PLOD1 indicates the efficacy of gene therapy DNA vector VTvaf17-COL7A1, gene therapy DNA vector VTvaf17-CLCA2, gene therapy DNA vector VTvaf17-ELN, gene therapy DNA vector VTvaf17-PLOD1, and confirms the feasibility of their use (especially after intradermal injection of gene therapy DNA vectors into human tissue).
[0532] Example 28.
[0533] Evidence of the efficacy of the gene therapy DNA vector VTvaf17-COL1A2 carrying the COL1A2 gene and the feasibility of its use to increase the expression level of COL1A2 protein in human tissues by injection of autologous fibroblasts transfected with the gene therapy DNA vector VTvaf17-COL1A2.
[0534] To confirm the efficacy of the gene therapy DNA vector VTvaf17-COL1A2 carrying the COL1A2 gene and the feasibility of its use, changes in COL1A2 protein concentration in the patient's skin were evaluated after injection of autologous fibroblast cultures of the same patient transfected with the gene therapy DNA vector VTvaf17-COL1A2.
[0535] Appropriate autologous fibroblast cultures transfected with the gene therapy DNA vector VTvaf17-COL1A2 carrying the COL1A2 gene are injected into the patient's forearm skin, along with a placebo in the form of autologous fibroblast cultures transfected with the gene therapy DNA vector VTvaf17 not carrying the COL1A2 gene.
[0536] Human primary fibroblast cultures were isolated from patient skin biopsy specimens. Using the skin biopsy device Epitheasy 3.5 (Medax SRL, Italy), biopsy specimens were taken from UV-protected areas, i.e., the skin behind the ear or on the inside of the elbow. The biopsy specimens were approximately 10 mm and about 11 mg. The patient's skin was initially rinsed with sterile saline and anesthetized with lidocaine solution. The primary cell culture was cultured in DMEM medium containing 10% fetal bovine serum and 100 U / ml ampicillin at 37°C in the presence of 5% CO2. The culture medium was subcultured and replaced every 2 days. The total duration of culture growth did not exceed 25-30 days. Then 5×10 4 The patient's fibroblast culture was transfected with a gene therapy DNA vector VTvaf17-COL1A2 carrying the COL1A2 gene and a placebo (ie, a VTvaf17 vector without the COL1A2 therapeutic gene).
[0537] According to the manufacturer's instructions, cationic polymers such as polyethyleneimine JETPEI (Polyplustransfection, France) are used for transfection. The cells are cultured for 72 hours and then injected into the patient. Autologous fibroblast cultures of patients transfected with the gene therapy DNA vector VTvaf17-COL1A2 and autologous fibroblast cultures of patients transfected with the gene therapy DNA vector VTvaf17 (as a placebo) are injected in the forearm using the channel method (wherein a 13mm long 30G needle to a depth of about 3mm). The concentration of modified autologous fibroblasts in the injected suspension is about 5ml of cells / 1ml of suspension, and the dose of the injected cells does not exceed 15mln. The injection point of the autologous fibroblast culture is located at 8 to 10cm intervals.
[0538] Biopsy samples were taken on the 4th day after injection of autologous fibroblast cultures transfected with gene therapy DNA vectors VTvaf17-COL1A2 carrying a therapeutic gene, i.e., COL1A2 gene, and placebo. Using the skin biopsy device Epitheasy 3.5 (Medax SRL, Italy), biopsies were taken from the patient's skin at the site of injection with autologous fibroblast cultures transfected with gene therapy DNA vectors VTvaf17-COL1A2 carrying a therapeutic gene, i.e., COL1A2 gene (C), autologous fibroblast cultures transfected with gene therapy DNA vectors VTvaf17 that do not carry the COL1A2 therapeutic gene (placebo) (B), and from the intact skin site (A). The patient's skin in the biopsy site was preliminarily rinsed with sterile saline and anesthetized with lidocaine solution. The biopsy sample volume was about 10 mm3 and the weight was about 11 mg. The sample was placed in a buffer solution containing 50 mM Tris-HCl (pH 7.6), 100 mM NaCl, 1 mM EDTA and 1 mM phenylmethylsulfonyl fluoride and homogenized to obtain a homogenized suspension. The suspension was then centrifuged at 14000 g for 10 minutes. The supernatant was collected and used to measure the therapeutic COL1A2 protein as described in Example 18.
[0539] The analysis results are as follows Fig.21 shown.
[0540] Fig.21 The results showed that the COL1A2 protein concentration in the area of the patient's skin at the injection site of the autologous fibroblast culture transfected with the gene therapy DNA vector VTvaf17-COL1A2 carrying the COL1A2 gene was increased compared with the COL1A2 protein concentration in the injection site of the autologous fibroblast culture transfected with the gene therapy DNA vector VTvaf17 (placebo) not carrying the COL1A2 gene, indicating the efficacy of the gene therapy DNA vector VTvaf17-COL1A2 so as to facilitate the feasibility of increasing the expression level of COL1A2 in human tissues (especially after injecting the skin with autologous fibroblasts transfected with the gene therapy DNA vector VTvaf17-COL1A2).
[0541] Example 29.
[0542] Evidence of the efficacy and feasibility of using a gene therapy DNA vector VTvaf17-COL1A1 carrying the COL1A1 gene, a gene therapy DNA vector VTvaf17-COL1A2 carrying the COL1A2 gene, a gene therapy DNA vector VTvaf17-P4HA1 carrying the P4HA1 gene, and a gene therapy DNA vector VTvaf17-P4HA2 carrying the P4HA2 gene in combination to increase the expression levels of COL1A1, COL1A2, P4HA1, and P4HA2 proteins in mammalian tissues.
[0543] After the mixture of gene therapy vectors was injected into three rats, changes in the concentrations of COL1A1, COL1A2, P4HA1, and P4HA2 proteins in the rat skin were evaluated.
[0544] The polyethyleneimine transfection reagent cGMP grade in vivo jetPEI (Polyplus Transfection, France) was used as a transport system. An equimolar mixture of gene therapy DNA vectors was dissolved in nuclease-free sterile water. To obtain the gene construct, the DNA-cGMP grade in vivo-JetPEI complex was prepared according to the manufacturer's recommendations. The injectable volume was 0.05 ml, with a total DNA amount of 100 μg. The solution was injected into the preliminarily depilated rat skin site using the tunneling method (with a 33G needle to a depth of 0.5 mm).
[0545] On the second day after the injection of the gene therapy DNA vector, a biopsy sample was taken. Using the skin biopsy device Epitheasy 3.5 (Medax SRL), biopsy samples were taken from the muscle site of the injection site of the mixture of gene therapy DNA vectors carrying the genes COL1A1, COL1A2, P4HA1 and P4HA2 (site I), the gene therapy DNA vector VTvaf17 (placebo) (site II), and from the intact skin site of the animal (site III). The biopsy sample site was initially rinsed with sterile saline and anesthetized with lidocaine solution. The biopsy sample volume was about 10mm3 and the weight was about 11mg. Each sample was placed in a buffer solution containing 50mMTris-HCl (pH7.6), 100mM NaCl, 1mM EDTA and 1mM phenylmethylsulfonyl fluoride, and homogenized to obtain a homogenized suspension. The suspension was then centrifuged at 14000g for 10 minutes. The supernatant was collected and used to measure the therapeutic protein, as described in Example 17 (quantification of COL1A1 protein), Example 18 (quantification of COL1A2 protein), Example 19 (quantification of P4HA1 protein) and Example 20 (quantification of P4HA2 protein). The analysis results are shown in Fig. 22 shown.
[0546] Fig. 22 It was shown that the concentrations of COL1A1, COL1A2, P4HA1 and P4HA2 proteins were increased in all rat skin sites (site I) injected with a mixture of gene therapy DNA vector VTvaf17-COL1A1 carrying COL1A1 therapeutic gene, gene therapy DNA vector VTvaf17-COL1A2 carrying COL1A2 therapeutic gene, gene therapy DNA vector VTvaf17-P4HA2 carrying P4HA2 therapeutic gene, and gene therapy DNA vector VTvaf17-P4HA2 carrying P4HA2 therapeutic gene, compared with site II (placebo site) and site III (intact site). The results indicate the efficacy of the combined use of gene therapy DNA vector VTvaf17-COL1A1, gene therapy DNA vector VTvaf17-COL1A2, gene therapy DNA vector VTvaf17-P4HA1 and gene therapy DNA vector VTvaf17-P4HA2 and their feasibility for increasing the expression level of therapeutic proteins in mammalian tissues.
[0547] Example 30.
[0548] Evidence for the efficacy of the gene therapy DNA vector VTvaf17-ELN carrying the ELN gene and the feasibility of its use to increase the expression level of ELN protein in mammalian cells.
[0549] To confirm the efficacy of the gene therapy DNA vector VTvaf17-ELN carrying the ELN gene, changes in ELN therapeutic gene mRNA accumulation in bovine dermal fibroblasts (ScienCell, Cat. #b2300) were evaluated 48 hours after BDFs were transfected with the gene therapy DNA vector VTvaf17-ELN carrying the human ELN gene.
[0550] Bovine dermal fibroblasts BDF were cultured in FM-2 medium (ScienCell, Cat. #2331). As described in Example 15, transfection, RNA extraction, reverse transcription reaction, PCR amplification and data analysis of the gene therapy DNA vector VTvaf17-ELN carrying the human ELN gene and the DNA vector VTvaf17 (reference) not carrying the human ELN gene were performed. The bull / cattle actin gene (ACT) listed in the GenBank database with the number AH001130.2 was used as a reference gene. The positive control included amplicons from PCR on a matrix represented by a plasmid containing ELN and ACT gene sequences at a known concentration. The negative control included deionized water. The PCR products, i.e., the ELN and ACT gene cDNA obtained by amplification, were quantified in real time using Bio-Rad CFX Manager 2.1 software (Bio-Rad, USA).
[0551] The analysis results are as follows Fig.23 shown.
[0552] Fig.23 The results show that the specific mRNA level of the human ELN gene was greatly increased due to the transfection of bovine dermal fibroblasts BDF with the gene therapy DNA vector VTvaf17-ELN, confirming the ability of the vector to penetrate into eukaryotic cells and express the ELN gene at the mRNA level. The results presented confirm the feasibility of using the gene therapy DNA vector VTvaf17-ELN in order to increase the expression level of the ELN gene in mammalian cells.
[0553] Example 31.
[0554] Escherichia coli strain SCS110-AF / VTvaf17-COL1A1, or Escherichia coli strain SCS110-AF / VTvaf17-COL1A2, or Escherichia coli strain SCS110-AF / VTvaf17-P4HA1, or Escherichia coli strain SCS110-AF / VTvaf17-P4HA2, or Escherichia coli strain SCS110-AF / VTvaf17-COL7A1, or Escherichia coli strain SCS110-AF / VTvaf17-CLCA2, or Escherichia coli strain SCS110-AF / VTvaf17-ELN, or Escherichia coli strain SCS110-AF / VTvaf17-PLOD1 carrying gene therapy DNA vector and method for producing the same.
[0555] Construction of a strain for producing a gene therapy DNA vector based on the gene therapy DNA vector VTvaf17 carrying a therapeutic gene (selected from the group consisting of the following genes: COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1) on an industrial scale, that is, carrying the gene therapy DNA vector VTvaf17-COL1A1, or VTvaf17-COL1A2, or VTvaf17-P4HA1, or VTvaf17-P4HA2, COL7A1, CLCA2, ELN and PLOD1, respectively. 2. E. coli strain SCS110-AF / VTvaf17-COL1A1, or E. coli strain SCS110-AF / VTvaf17-COL1A2, or E. coli strain SCS110-AF / VTvaf17-P4HA1, or E. coli strain SCS110-AF / VTvaf17-P4HA1 or VTvaf17-CLCA2, or VTvaf17-ELN, or VTvaf17-PLOD1 2. or E. coli strain SCS110-AF / VTvaf17-COL7A1, or E. coli strain SCS110-AF / VTvaf17-CLCA2, or E. coli strain SCS110-AF / VTvaf17-ELN, or E. coli strain SCS110-AF / VTvaf17-PLOD1, for production thereof, allowing for no antibiotic selection, involving the preparation of electrocompetent cells of E. coli strain SCS110-AF, and using the gene therapy DNA vector VTvaf17-C These cells were electroporated with VTvaf17-OL1A1, VTvaf17-COL1A2, VTvaf17-P4HA1, VTvaf17-P4HA2, VTvaf17-COL7A1, VTvaf17-CLCA2, VTvaf17-ELN, VTvaf17-PLOD1. The cells were then plated on agar plates (petri dishes) with a selective medium containing yeast, peptone, 6% sucrose, and 10 μg / ml chloramphenicol.At the same time, the Escherichia coli strain SCS110-AF was generated to produce the gene therapy DNA vector VTvaf17 or a gene therapy DNA vector based on the gene therapy DNA vector VTvaf17, allowing antibiotic-free positive selection, which involved constructing a 64 bp linear DNA fragment containing the regulatory element RNA-IN of the transposon Tn10 allowing antibiotic-free positive selection; the 1422 bp levansucrase gene sacB, whose product ensures selection in a sucrose-containing medium, the 763 bp chloramphenicol resistance gene catR required for strain clones in which homologous recombination occurs, and two homologous sequences of 329 bp and 233 bp, ensuring homologous recombination in the region of the gene recA simultaneously with gene inactivation, and then the Escherichia coli cells were transformed by electroporation, and clones surviving in a medium containing 10 μg / ml chloramphenicol were selected.
[0556] The strains obtained for production are included in the collections of the National Biological Resource Centre - Russian National Collection of Industrial Microorganisms (NBRC RNCIM), the RF of the United Kingdom and the NCIMB Patent Deposit Service under the following accession numbers:
[0557] Escherichia coli strain SCS110-AF / VTvaf17-COL1A1-registered in the Russian National Collection of Industrial Microorganisms under the number B-13165, deposited on May 11, 2018; International Depository Authority (INTERNATIONAL DEPOSITARYAUTHORITY) number NCIMB 43033, deposited on April 20, 2018,
[0558] Escherichia coli strain SCS110-AF / VTvaf17-COL1A2-registered in the Russian National Collection of Industrial Microorganisms under the number B-13164, deposited on May 11, 2018; International Depository Authority (INTERNATIONALDEPOSITARYAUTHORITY) number NCIMB 43035, deposited on April 20, 2018,
[0559] Escherichia coli strain SCS110-AF / VTvaf17-P4HA1-registered in the Russian National Collection of Industrial Microorganisms under the number B-13384, deposited on December 14, 2018; International Depository Authority (INTERNATIONALDEPOSITARYAUTHORITY) number NCIMB 43311, deposited on December 13, 2018,
[0560] Escherichia coli strain SCS110-AF / VTvaf17-P4HA2-registered in the Russian National Collection of Industrial Microorganisms under the number B-13388, deposited on December 14, 2018; International Depository Authority (INTERNATIONAL DEPOSITARYAUTHORITY) number NCIMB 43312, deposited on December 13, 2018,
[0561] Escherichia coli strain SCS110-AF / VTvaf17-CLCA2-registered in the Russian National Collection of Industrial Microorganisms under the number B-13385, deposited on December 14, 2018; International Depository Authority (INTERNATIONAL DEPOSITARYAUTHORITY) number NCIMB 43308, deposited on December 13, 2018,
[0562] Escherichia coli strain SCS110-AF / VTvaf17-ELN-registered in the Russian National Collection of Industrial Microorganisms under the number B-13341, deposited on November 22, 2018; International Depository Authority (INTERNATIONAL DEPOSITARYAUTHORITY) number NCIMB 43281, deposited on November 22, 2018,
[0563] The Escherichia coli strain SCS110-AF / VTvaf17-PLOD1 is registered in the Russian National Collection of Industrial Microorganisms under the number B-13387, with a deposit date of December 14, 2018; the international depository authority (INTERNATIONAL DEPOSITARYAUTHORITY) number is NCIMB 43313, with a deposit date of December 13, 2018.
[0564] Example 32.
[0565] A method for scaling up to industrial scale a gene therapy DNA vector VTvaf17 based on a gene therapy DNA vector VTvaf17 carrying a therapeutic gene (selected from the group consisting of COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1).
[0566] To confirm the gene therapy DNA vectors VTvaf17-COL1A1 (SEQ ID No. 1), or VTvaf17-COL1A2 (SEQ ID No. 2), or VTvaf17-P4HA1 (SEQ ID No. 3), or VTvaf17-P4HA2 (SEQ ID No. 4), or VTvaf17-COL7A1 (SEQ ID No. 5), or VTvaf17-CLCA2 (SEQ ID No. 6), or VTvaf17-ELN (SEQ ID No. 7), or VTvaf17-PLOD1 (SEQ ID No. 8). No.8) The manufacturability and constructability on an industrial scale are for E. coli strain SCS110-AF / VTvaf17-COL1A1, or E. coli strain SCS110-AF / VTvaf17-COL1A2, or E. coli strain SCS110-AF / VTvaf17-P4HA1, or E. coli strain SCS110-AF / VTvaf17-P4HA2, or E. coli strain SCS110-AF / VTvaf17-COL7A1, or E. coli Strain SCS110-AF / VTvaf17-CLCA2, or Escherichia coli strain SCS110-AF / VTvaf17-ELN, or Escherichia coli strain SCS110-AF / VTvaf17-PLOD1 (each containing a gene therapy DNA vector VTvaf17 carrying a region of a therapeutic gene (i.e., COL1A1, or COL1A2, or P4HA1, or P4HA2, or COL7A1, or CLCA2, or ELN, or PLOD1)) were subjected to large-scale fermentation.Each E. coli strain SCS110-AF / VTvaf17-COL1A1, or E. coli strain SCS110-AF / VTvaf17-COL1A2, or E. coli strain SCS110-AF / VTvaf17-P4HA1, or E. coli strain SCS110-AF / VTvaf17-P4HA2, or E. coli strain SCS110-AF / VTvaf17-COL7A1, or E. coli strain SCS110-AF / VTvaf17-CLCA2, or E. coli SCS110-AF / VTvaf17-ELN, or E. coli SCS110-AF / VTvaf17-PLOD1 was based on E. coli strain SCS110-AF (Cell and Gene Therapy LLC, United States). Kingdom) was produced by the following method, as described in Example 31: competent cells of the strain were electroporated with gene therapy DNA vectors VTvaf17-COL1A1, or VTvaf17-COL1A2, or VTvaf17-P4HA1, or VTvaf17-P4HA2, or VTvaf17-COL7A1, or VTvaf17-CLCA2, or VTvaf17-ELN, or VTvaf17-PLOD1 carrying therapeutic genes (i.e., COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN, and PLOD1), wherein the transformed cells were further plated on agar plates (petri dishes) with selective medium, and individual clones were selected, wherein the selective medium contained yeast extract, peptone, and 6% sucrose.
[0567] The Escherichia coli SCS110-AF / VTvaf17-COL1A1 strain carrying the gene therapy DNA vector VTvaf17-COL1A1 was fermented in a 10L fermenter, and then the gene therapy DNA vector VTvaf17-COL1A1 was extracted.
[0568] For the fermentation of E. coli strain SCS110-AF / VTvaf17-COL1A1, a medium containing the following ingredients per 10L volume was prepared: 100 g of tryptone and 50 g of yeast extract (Becton Dickinson, USA); the medium was then diluted to 8800 ml with water, autoclaved at 121°C for 20 minutes, and then 1200 ml of 50% (w / v) sucrose was added. After that, a seed culture of the E. coli strain SCS110-AF / VTvaf17-COL1A1 was inoculated into a culture flask with a volume of 100 ml. The culture was incubated in a shaking incubator at 30°C for 16 hours. The seed culture was transferred to a Techfors S bioreactor (Infors HT, Switzerland) and grown to the stationary phase. The process was controlled by measuring the optical density of the culture at 600 nm. The cells were pelleted at 5000-10000g for 30 minutes. Remove the supernatant and resuspend the cell pellet in 10% (by volume) phosphate buffered saline. The cells are centrifuged again at 5000-10000g for 30 minutes. Remove the supernatant, add 20mM TrisCl, 1mM EDTA, 200g / L sucrose (pH 8.0) solution to the cell pellet in a volume of 1000mL, and stir the mixture thoroughly to a homogenized suspension. Then add egg lysozyme solution to a final concentration of 100μg / ml. Incubate the mixture on ice for 20 minutes while stirring gently. Then add 0.2M NaOH 2500ml, 10g / L sodium dodecyl sulfate (SDS), incubate the mixture on ice for 10 minutes while stirring gently, then add 3M sodium acetate 2M acetic acid 3500ml (pH5-5.5), and incubate the mixture on ice for 10 minutes while stirring gently. The resulting sample was centrifuged at 15,000g or greater for 20-30 minutes. The solution was carefully decanted and the residual precipitate was removed by a coarse filter (filter paper). Then, RNase A (Sigma, USA) was added to a final concentration of 20μg / ml, and the solution was incubated at room temperature for 16 hours overnight. The solution was then centrifuged at 15,000g for 20-30 minutes and passed through a 0.45μm membrane filter ((Millipore, USA). Then, ultrafiltration was performed using a 100kDa membrane (Millipore, USA), and the mixture was diluted to the initial volume with a 25mM TrisCl buffer solution (pH7.0). This operation was performed three to four times. The solution was applied to a column containing 250ml of DEAE Sepharose HP (GE, USA), balanced with 25mM TrisCl, pH7.0.After loading, the column was washed with three volumes of the same solution and then balanced with 25mM TrisCl (pH 7.0). After loading, the column was washed with three volumes of the same solution, and then the gene therapy DNA vector VTvaf17-COL1A1 was eluted using a linear gradient of 25mM TrisCl (pH 7.0) to obtain a solution of 25mM TrisCl (pH 7.0), 1M NaCl, which was 5 times the column volume. The elution process was controlled by measuring the optical density of the effluent at 260nm. The chromatographic fractions containing the gene therapy DNA vector VTvaf17-COL1A1 were combined and gel filtered using Superdex 200 (GE, USA). The column was balanced with phosphate buffered saline. The elution process was controlled by measuring the optical density of the effluent at 260nm, and the fractions were analyzed by agarose gel electrophoresis. The fractions containing the gene therapy DNA vector VTvaf17-COL1A1 were combined and stored at -20°C. To evaluate the reproducibility of the process, the designated operation was repeated five times. All treatment operations for E. coli strain SCS110-AF / VTvaf17-COL1A2, or E. coli strain SCS110-AF / VTvaf17-P4HA1, or E. coli strain SCS110-AF / VTvaf17-P4HA2, or E. coli strain SCS110-AF / VTvaf17-COL7A1, or E. coli strain SCS110-AF / VTvaf17-CLCA2, or E. coli strain SCS110-AF / VTvaf17-ELN, or E. coli strain SCS110-AF / VTvaf17-PLOD1 were performed in a similar manner.
[0569] The processing reproducibility and quantitative characteristics of the final product yield confirm the producibility and constructibility of the gene therapy DNA vectors VTvaf17-COL1A1, or VTvaf17-COL1A2, or VTvaf17-P4HA1, or VTvaf17-P4HA2, or VTvaf17-COL7A1, or VTvaf17-CLCA2, or VTvaf17-ELN, or VTvaf17-PLOD1 on an industrial scale.
[0570] Therefore, the resulting gene therapy DNA vector containing a therapeutic gene can be used to deliver it to cells of humans and animals experiencing reduced or insufficient expression of the protein encoded by the gene, thereby ensuring the desired therapeutic effect.
[0571] The present invention sets the object of constructing a gene therapy DNA vector to increase the expression level of COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1 genes, combining the following properties:
[0572] 1) improving the efficacy of therapeutic gene expression in eukaryotic cells due to the limited size of the vector portion of the resulting gene therapy vector,
[0573] II) the possibility of safe use in gene therapy for humans and animals due to the lack of regulatory elements and antibiotic resistance genes representing viral genomic nucleotide sequences in gene therapy DNA vectors, III) the manufacturability and constructability of strains on an industrial scale,
[0574] IV) and the purpose of constructing strains carrying these gene therapy DNA vectors for producing these gene therapy DNA vectors, which is supported by the following examples:
[0575] For I - Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30;
[0576] For II - Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30;
[0577] For III - Examples 1, 2, 3, 4, 5, 6, 7, 8, 31, 32;
[0578] For IV-Examples 31, 32.
[0579] Industrial Applicability
[0580] All the examples listed above demonstrate that the proposed gene therapy DNA vector based on the gene therapy DNA vector VTvaf17 carrying therapeutic genes (selected from the group consisting of COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1 genes) can increase the expression level of these therapeutic genes, and the Escherichia coli strain SCS110-AF / VTvaf17-COL1A1, or the Escherichia coli strain SCS110-AF / VTvaf17-COL1A2, or The industrial applicability of Escherichia coli strain SCS110-AF / VTvaf17-P4HA1, or Escherichia coli strain SCS110-AF / VTvaf17-P4HA2, or Escherichia coli strain SCS110-AF / VTvaf17-COL7A1, or Escherichia coli strain SCS110-AF / VTvaf17-CLCA2, or Escherichia coli strain SCS110-AF / VTvaf17-ELN, or Escherichia coli strain SCS110-AF / VTvaf17-PLOD1, and their production methods on an industrial scale.
[0581] Abbreviations:
[0582] VTvaf17 - Gene therapy vector lacking viral genome and antibiotic resistance marker sequences (virus-free antibiotic therapeutic vector)
[0583] DNA: deoxyribonucleic acid
[0584] cDNA: complementary deoxyribonucleic acid
[0585] RNA: ribonucleic acid
[0586] mRNA: messenger ribonucleic acid
[0587] bp: base pair
[0588] PCR: polymerase chain reaction
[0589] ml: milliliter, μl: microliter
[0590] mm3: cubic millimeter
[0591] l: rise
[0592] μg: microgram
[0593] mg: milligram
[0594] g: grams
[0595] μM: micromolar
[0596] mM: millimole
[0597] min: minutes
[0598] s: seconds
[0599] rpm: revolutions per minute
[0600] nm: nanometer
[0601] cm: centimeters
[0602] mW: milliwatt
[0603] RFU: relative fluorescence unit
[0604] PBS: Phosphate buffered saline
[0605] References
[0606] 1. Bart G, L,Rauhala L,Salonen P,Kokkonen M,Dunlop TW,Pehkonen P,Kumlin T,Tammi MI, S, Tammi RH. rClca2 is associated with epidermal differentiation and is strongly downregulated by ultraviolet radiation. Br J Dermatol. 2014Aug;171(2):376–87.
[0607] 2.Connon CJ, Yamasaki K, Kawasaki S, Quantock AJ, Koizumi N, Kinoshita S. Calcium-activated chloride channel-2in human epithelia. J HistochemCytochem. 2004Mar; 52(3):415–8.
[0608] 3. Craven et al., 1997
[0609] 4.Draft Guideline on the quality,non-clinical and clinical aspects ofgene therapy medicinal products,http: / / www.ema.europa.eu / docs / en_GB / document_library / Scientific_guideline / 2015 / 05 / WC500187020.pdf
[0610] 5.Ewart AK,Jin W,Atkinson D,Morris CA,Keating MT.Supravalvular aorticstenosis associated with a deletion disrupting the elastin gene.J ClinInvest.1994Mar;93(3):1071–7.
[0611] 6.Georgiadis C,Syed F,Petrova A,Abdul-Wahab A,Lwin SM,Farzaneh F,ChanL,Ghani S,Fleck RA,Glover L,McMillan JR,Chen M,Thrasher AJ,McGrath JA,Di WL,Qasim W.Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1Restore Anchoring Fibrils in RDEB.J Invest Dermatol.2016Jan;136(1):284–92.
[0612] 7.Goto M,Sawamura D,Ito K,Abe M,Nishie W,Sakai K,Shibaki A,Akiyama M,Shimizu H.Fibroblasts show more potential as target cells than keratinocytesin COL7A1 gene therapy of dystrophic epidermolysis bullosa.J InvestDermatol.2006Apr;126(4):766–72.
[0613] 8.Guideline on the quality,non-clinical and clinical aspects of gene therapy medicinal products EMA / CAT / 80183 / 2014
[0614] 9.Hatzimichael E,Lo Nigro C,Lattanzio L,Syed N,Shah R,Dasoula A,Janczar K,Vivenza D,Monteverde M,Merlano M,Papoudou-Bai A,Bai M,Schmid P,Stebbing J,Bower M,Dyer MJ,Karran LE,ElguetaKarstegl C,Farrell PJ,Thompson A,Briasoulis E,Crook T.Collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma.Br J Cancer.2012 Oct 9,107(8):1423–32.
[0615] 10.Hornstein BD,Roman D,Arévalo-Soliz LM,Engevik MA,ZechiedrichL.Effects of Circular DNA Length on Transfection Efficiency byElectroporation into HeLa Cells. V,ed.PLoS ONE.2016:11(12):e0167537.
[0616] 11.Jacków J,Titeux M,Portier S,Charbonnier S,Ganier C,Gaucher S,Hovnanian A.Gene-Corrected Fibroblast Therapy for Recessive DystrophicEpidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector.JInvest Dermatol.2016 Jul;136(7):1346–1354.
[0617] 12.Keene DR,Sakai LY,Lunstrum GP,Morris NP,Burgeson RE.Type VIIcollagen forms an extended network of anchoring fibrils.J Cell Biol.1987 Mar;104(3):611–21.
[0618] 13.Kielty CM,Sherratt MJ,Shuttleworth CA.Elastic fibres.J CellSci.2002 Jul 15;115(Pt 14):2817–28.
[0619] 14.Labat-Robert J.Cell-matrix interactions,alteration with aging andage associated diseases.A review.Pathol Biol(Paris).2001 May;49(4):349–52.
[0620] 15.Li L,Petrovsky N.Molecular mechanisms for enhanced DNA vaccineimmunogenicity.Expert Rev Vaccines.2016;15(3):313–29
[0621] 16.Li SH,Sun Z,Guo L,Han M,Wood MF,Ghosh N,Vitkin IA,Weisel RD,LiRK.Elastin overexpression by cell-based gene therapy preserves matrix andprevents cardiac dilation.J Cell Mol Med.2012 Oct16(10):2429–39.
[0622] 17.Mairhofer J,Grabherr R.Rational vector design for efficient non-viral gene delivery:challenges facing the use of plasmid DNA.MolBiotechnol.2008.39(2):97–104
[0623] 18.Majka,Magdalena Janeczko,Jolanta Danuta Jarocha,Alexandra Joanna Witecka,Marta Lesiak,Halina Koryciak-Komarska,Aleksander L.Sieroń,Jacek Jozef Pietrzyk,Open Journal of Genetics,Vol.3 No.1,2013
[0624] 19.Mecklenbeck S,Compton SH,Mejía JE,Cervini R,Hovnanian A,Bruckner-Tuderman L,Barrandon YA microinjected COL7A1-PAC vector restores synthesisof intact procollagen VII in a dystrophic epidermolysis bullosa keratinocytecell line.Hum Gene Ther.2002 Sep 1;13(13):1655–62.
[0625] 20.Mencia ,Chamorro C,Bonafont J,Duarte B,Holguin A,Illera N,LlamesSG,Escámez MJ,Hausser I,Del Río M,Larcher F,Murillas R.Deletion of a Pathogenic Mutation-Containing Exon of COL7A1 Allows Clonal Gene EditingCorrection of RDEB Patient Epidermal Stem Cells.Mol Ther Nucleic Acids.2018Jun 1;11:68–78.
[0626] 21. Napolitano F, Di Iorio V, Testa F, Tirozzi A, Reccia MG, Lombardi L, Farina O, Simonelli F, Gianfrancesco F, Di Iorio G, Melone MAB, Esposito T, Sampaolo S. Autosomal-dominant myopia associated with a novel P4HA2 missensevariant and defective collagen hydroxylation. Clin Genet. 2018 May;93(5):982–991.
[0627] 22.Naylor EC,Watson RE,Sherratt MJ.Molecular aspects of skin aging.Maturitas.2011 Jul:69(3):249–5
[0628] 23.Ortiz-Urda S,Thyagarajan B,Keene DR,Lin Q,Fang M,Calos MP,KhavariPA.Stable nonviral genetic correction of inherited human skin disease.NatMed.2002 Oct18(10):1166–70.Epub 2002 Sep 16.Erratum in:Nat Med.2003 Feb9(2):237.
[0629] 24.Osborn MJ,Starker CG,McElroy AN,Webber BR,Riddle MJ,Xia L,DeFeoAP,Gabriel R,Schmidt M,von Kalle C,Carlson DF,Maeder ML,Joung JK,Wagner JE,Voytas DF,Blazar BR,Tolar J.TALEN-based gene correction for epidermolysisbullosa.Mol Ther.2013 Jun21(6):1151–9.
[0630] Biochem Biophys Res Commun.2004 Oct 15;323(2):592–8.25.Raveendran M,Senthil D,Utama B,Shen Y,Dudley D,Wang J,Zhang Y,WangXL.2004 Oct 15;323(2):592–8.
[0631] 26.Reflection paper on design modifications of gene therapy medicinalproducts during development / 14 December 2011 EMA / CAT / GTWP / 44236 / 2009Committee for advanced therapies
[0632] 27.Ritz-Timme et al.,2003
[0633] 28.Santos VJ.High Throughput Screen for molecules and metaboliteswith potential cosmetic application UNIVERSIDADE DE LISBOA,Mestrado emMicrobiologia Aplicada,2010.
[0634] 29.Seltmann K,Meyer M,Sulcova J,Kockmann T,Wehkamp U,Weidinger S,Aufdem Keller U,Werner S.Humidity-regulated CLCA2 protects the epidermis fromhyperosmotic stress.Sci Transl Med.2018 May 9;10(440).
[0635] 30.Talwar HS,Griffiths CE,Fisher GJ,Hamilton TA,Voorhees JJ.Reducedtype I and type III procollagens in photodamaged adult human skin.J InvestDermatol.
[0636] 31.1995 Aug;105(2):285–90.Tasker PN,Macdonald H,Fraser WD,Reid DM,Ralston SH,Albagha OM.Association of PLOD1 polymorphisms with bone mineraldensity in a population-based study of women from the UK.Osteoporos Int.2006;17(7):1078–85.
[0637] 32.Uchinaka A,Kawaguchi N,Hamada Y,Miyagawa S,Saito A,Mori S,Sawa Y,Matsuura N.Transplantation of elastin-secreting myoblast sheets improvescardiac function in infarcted rat heart.Mol Cell Biochem.2012 Sep;368(1-2):203–14.
[0638] 33.van Dijk FS,Mancini GMS,Maugeri A,Cobben JM.Ehlers Danlossyndrome,kyphoscoliotic type due to Lysyl Hydroxylase 1 deficiency in twochildren without congenital or early onset kyphoscoliosis.Eur J MedGenet.2017 Oct;60(10):536–540.
[0639] 34.Woodley DT,Keene DR,Atha T,Huang Y,Ram R,Kasahara N,ChenM.Intradermal injection of lentiviral vectors corrects regenerated humandystrophic epidermolysis bullosa skin tissue in vivo.Mol Ther.2004 Aug;10(2):318–26.
[0640] 35.Zou Y,Donkervoort S,Salo AM,Foley AR,Barnes AM,Hu Y,Makareeva E,Leach ME,Mohassel P,Dastgir J,Deardorff MA,Cohn RD,DiNonno WO,Malfait F,LekM,Leikin S,Marini JC,Myllyharju J, CG.P4HA1 mutations cause a unique congenital disorder of connective tissue involving tendon,bone,muscleand the eye.Hum Mol Genet.2017 Jun 15:26(12):2207–2217.
[0641] 36.Biochemistry:A Textbook for Higher Education Institutions,edited byE.S.Severin.,2003.p.779 ISBN 5-9231-0254-4
[0642] 37.Molecular Biology,2011,Vol.45,No.1,pp.44–55
[0643] 38.SSKuznetsov,VVDudenkova,MVKochueva,EBKiseleva,N.Yu.Ignatieva,OLZakharkin,EASergeeva,KVBabak,AVMaslennikov.Multiphoton microscopy in the study of morphologicalcharacteristics of radiation-induced injuries of the bladder medicine,2016,volume 8,number 2,pp.31–39.
[0644] 39.Urology:textbook / BKKomyakov.–2012.–p.464
Claims
1. A recombinant DNA vector based on the gene therapy DNA vector VTvaf17, which carries a therapeutic gene selected from the group of genes COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1, wherein the recombinant DNA vector has the coding region of the selected therapeutic gene cloned into the gene therapy DNA vector VTvaf17, forming a recombinant DNA vector VTvaf17-COL1A1 having a nucleotide sequence of SEQ ID No. 1 or VTvaf17-COL1A2 having a nucleotide sequence of SEQ ID No. 2, or VTvaf17-P4HA1 having a nucleotide sequence of SEQ ID No. 3 or VTvaf17-P4HA2 having a nucleotide sequence of SEQ ID No. 4 or VTvaf17-COL7A1 having a nucleotide sequence of SEQ ID No. 5 or VTvaf17-CLCA2 having a nucleotide sequence of SEQ ID No. 6 or VTvaf17- having a nucleotide sequence of SEQ ID No.
7. ELN or VTvaf17-PLOD1 having the nucleotide sequence SEQ ID No.
8.
2. A method for producing a recombinant DNA vector based on the gene therapy DNA vector VTvaf17 according to claim 1, wherein the recombinant DNA vector carries a therapeutic gene selected from the group consisting of COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN and PLOD1 genes, the method comprising obtaining each of the recombinant DNA vectors as follows: VTvaf17-COL1A1, or VTvaf17-COL1A2, or VTvaf17-P4HA1, or VTvaf17-P4HA2, or VTvaf17-COL7A1, or VTvaf17-CLCA2, or VTvaf17-ELN, or VTvaf17-PLOD1: COL1A1, or COL1A2, or P4HA1, or P4HA2, or COL7A1, or CLCA2, or ELN, or PLOD1 according to claim 1. or PLOD1 therapeutic gene coding region is cloned into the gene therapy DNA vector VTvaf17, and the recombinant DNA vector VTvaf17-COL1A1, SEQID No. 1, or VTvaf17-COL1A2, SEQ ID No. 2, or VTvaf17-P4HA1, SEQ ID No. 3, or VTvaf17-P4HA2, SEQ ID No. 4, or VTvaf17-COL7A1, SEQ ID No. 5, or VTvaf17-CLCA2, SEQ ID No. 6, or VTvaf17-ELN, SEQ ID No. 7, or VTvaf17-PLOD1, SEQ ID No. 8 is obtained respectively, wherein the COL1A1, or COL1A2, or P4HA1, or P4HA2, or COL7A1, or CLCA2, or ELN, or the coding region of the PLOD1 therapeutic gene is obtained by isolating total RNA from a human biological tissue sample, followed by reverse transcription reaction and PCR amplification using the obtained oligonucleotides, and cutting the amplified product by corresponding restriction endonucleases, wherein cloning of the gene therapy DNA vector VTvaf17 is performed at NheI and HindIII restriction sites, wherein selection is performed in the absence of antibiotics, and wherein the method for producing the recombinant DNA vector allows the production volume of the recombinant DNA vector to be scaled up to an industrial level.
3. An Escherichia coli strain carrying the recombinant DNA vector according to claim 1.
